Cover
Cover - shares | 9 Months Ended | |
Sep. 30, 2022 | Oct. 28, 2022 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Sep. 30, 2022 | |
Document Transition Report | false | |
Entity File Number | 000-33043 | |
Entity Registrant Name | OMNICELL, INC | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 94-3166458 | |
Entity Address, Address Line One | 2625 Augustine Drive | |
Entity Address, Address Line Two | Suite 301 | |
Entity Address, City or Town | Santa Clara | |
Entity Address, State or Province | CA | |
Entity Address, Postal Zip Code | 95054 | |
City Area Code | 650 | |
Local Phone Number | 251-6100 | |
Title of 12(b) Security | Common Stock, $0.001 par value | |
Trading Symbol | OMCL | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Large Accelerated Filer | |
Entity Small Business | false | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 44,649,842 | |
Entity Central Index Key | 0000926326 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Year Focus | 2022 | |
Document Fiscal Period Focus | Q3 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Current assets: | ||
Cash and cash equivalents | $ 266,402 | $ 349,051 |
Accounts receivable and unbilled receivables, net of allowances of $5,012 and $5,272, respectively | 354,098 | 240,894 |
Inventories | 147,096 | 119,924 |
Prepaid expenses | 24,862 | 22,499 |
Other current assets | 56,674 | 48,334 |
Total current assets | 849,132 | 780,702 |
Property and equipment, net | 88,356 | 71,141 |
Long-term investment in sales-type leases, net | 33,807 | 18,391 |
Operating lease right-of-use assets | 44,133 | 48,549 |
Goodwill | 731,294 | 738,900 |
Intangible assets, net | 251,004 | 277,616 |
Long-term deferred tax assets | 16,619 | 15,883 |
Prepaid commissions | 54,994 | 63,795 |
Other long-term assets | 110,346 | 127,519 |
Total assets | 2,179,685 | 2,142,496 |
Current liabilities: | ||
Accounts payable | 73,517 | 71,513 |
Accrued compensation | 42,799 | 71,130 |
Accrued liabilities | 146,440 | 133,167 |
Deferred revenues, net | 113,925 | 112,196 |
Convertible senior notes, net | 0 | 488,152 |
Total current liabilities | 376,681 | 876,158 |
Long-term deferred revenues | 34,519 | 20,194 |
Long-term deferred tax liabilities | 16,140 | 51,705 |
Long-term operating lease liabilities | 41,862 | 39,911 |
Other long-term liabilities | 9,285 | 7,839 |
Convertible senior notes, net | 565,803 | 0 |
Total liabilities | 1,044,290 | 995,807 |
Commitments and contingencies (Note 13) | ||
Stockholders’ equity: | ||
Preferred stock, $0.001 par value, 5,000 shares authorized; no shares issued | 0 | 0 |
Common stock, $0.001 par value, 100,000 shares authorized; 54,929 and 54,073 shares issued; 44,646 and 44,179 shares outstanding, respectively | 55 | 54 |
Treasury stock at cost, 10,283 and 9,894 shares outstanding, respectively | (290,319) | (238,109) |
Additional paid-in capital | 1,030,665 | 1,024,580 |
Retained earnings | 419,136 | 368,571 |
Accumulated other comprehensive loss | (24,142) | (8,407) |
Total stockholders’ equity | 1,135,395 | 1,146,689 |
Total liabilities and stockholders’ equity | $ 2,179,685 | $ 2,142,496 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) shares in Thousands, $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Statement of Financial Position [Abstract] | ||
Allowance for credit losses on accounts receivable and unbilled receivables | $ 5,012 | $ 5,272 |
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized (in shares) | 5,000 | 5,000 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, shares authorized (in shares) | 100,000 | 100,000 |
Common Stock, shares issued (in shares) | 54,929 | 54,073 |
Common stock, shares outstanding (in shares) | 44,646 | 44,179 |
Treasury stock, shares outstanding (in shares) | 10,283 | 9,894 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Revenues | $ 348,059 | $ 296,402 | $ 998,273 | $ 820,984 |
Cost of revenues | 188,964 | 149,623 | 531,039 | 415,624 |
Gross profit | 159,095 | 146,779 | 467,234 | 405,360 |
Operating expenses: | ||||
Research and development | 25,171 | 19,477 | 76,556 | 53,770 |
Selling, general, and administrative | 115,459 | 97,910 | 354,644 | 273,672 |
Total operating expenses | 140,630 | 117,387 | 431,200 | 327,442 |
Income from operations | 18,465 | 29,392 | 36,034 | 77,918 |
Interest and other income (expense), net | (1,148) | (6,065) | (2,973) | (18,715) |
Income before provision for income taxes | 17,317 | 23,327 | 33,061 | 59,203 |
Provision for (benefit from) income taxes | 543 | (5,990) | (995) | (4,665) |
Net income | $ 16,774 | $ 29,317 | $ 34,056 | $ 63,868 |
Net income per share: | ||||
Basic (in dollars per share) | $ 0.38 | $ 0.67 | $ 0.77 | $ 1.48 |
Diluted (in dollars per share) | $ 0.37 | $ 0.61 | $ 0.73 | $ 1.35 |
Weighted-average shares outstanding: | ||||
Basic (in shares) | 44,441 | 43,648 | 44,304 | 43,293 |
Diluted (in shares) | 45,819 | 48,341 | 46,759 | 47,195 |
Product revenues | ||||
Revenues | $ 246,565 | $ 213,970 | $ 706,246 | $ 589,006 |
Cost of revenues | 134,023 | 110,743 | 374,175 | 303,597 |
Services and other revenues | ||||
Revenues | 101,494 | 82,432 | 292,027 | 231,978 |
Cost of revenues | $ 54,941 | $ 38,880 | $ 156,864 | $ 112,027 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Statement of Comprehensive Income [Abstract] | ||||
Net income | $ 16,774 | $ 29,317 | $ 34,056 | $ 63,868 |
Other comprehensive loss: | ||||
Foreign currency translation adjustments | (6,770) | (2,299) | (15,735) | (2,268) |
Other comprehensive loss | (6,770) | (2,299) | (15,735) | (2,268) |
Comprehensive income | $ 10,004 | $ 27,018 | $ 18,321 | $ 61,600 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands | Total | Cumulative effect of a change in accounting principle related to convertible debt | Common Stock | Treasury Stock | Additional Paid-In Capital | Additional Paid-In Capital Cumulative effect of a change in accounting principle related to convertible debt | Accumulated Earnings | Accumulated Earnings Cumulative effect of a change in accounting principle related to convertible debt | Accumulated Other Comprehensive Income (Loss) |
Balance at beginning of period (in shares) at Dec. 31, 2020 | 52,677,000 | ||||||||
Balance at beginning of period at Dec. 31, 2020 | $ 967,503 | $ 53 | $ (238,109) | $ 920,359 | $ 290,722 | $ (5,522) | |||
Balance at beginning of period, Treasury stock (in shares) at Dec. 31, 2020 | (9,894,000) | ||||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||||
Net income | 14,127 | 14,127 | |||||||
Other comprehensive income (loss) | (621) | (621) | |||||||
Share-based compensation | 11,772 | 11,772 | |||||||
Issuance of common stock under employee stock plans (in shares) | 388,000 | ||||||||
Issuance of common stock under employee stock plans | 20,826 | 20,826 | |||||||
Tax payments related to restricted stock units | (2,596) | (2,596) | |||||||
Balance at end of period (in shares) at Mar. 31, 2021 | 53,065,000 | ||||||||
Balance at end of period at Mar. 31, 2021 | 1,011,011 | $ 53 | $ (238,109) | 950,361 | 304,849 | (6,143) | |||
Balance at end of period, Treasury stock (in shares) at Mar. 31, 2021 | (9,894,000) | ||||||||
Balance at beginning of period (in shares) at Dec. 31, 2020 | 52,677,000 | ||||||||
Balance at beginning of period at Dec. 31, 2020 | 967,503 | $ 53 | $ (238,109) | 920,359 | 290,722 | (5,522) | |||
Balance at beginning of period, Treasury stock (in shares) at Dec. 31, 2020 | (9,894,000) | ||||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||||
Net income | 63,868 | ||||||||
Other comprehensive income (loss) | (2,268) | ||||||||
Balance at end of period (in shares) at Sep. 30, 2021 | 53,763,000 | ||||||||
Balance at end of period at Sep. 30, 2021 | 1,111,336 | $ 54 | $ (238,109) | 1,002,591 | 354,590 | (7,790) | |||
Balance at end of period, Treasury stock (in shares) at Sep. 30, 2021 | (9,894,000) | ||||||||
Balance at beginning of period (in shares) at Dec. 31, 2020 | 52,677,000 | ||||||||
Balance at beginning of period at Dec. 31, 2020 | $ 967,503 | $ 53 | $ (238,109) | 920,359 | 290,722 | (5,522) | |||
Balance at beginning of period, Treasury stock (in shares) at Dec. 31, 2020 | (9,894,000) | ||||||||
Balance at end of period (in shares) at Dec. 31, 2021 | 44,179,000 | 54,073,000 | |||||||
Balance at end of period at Dec. 31, 2021 | $ 1,146,689 | $ (56,233) | $ 54 | $ (238,109) | 1,024,580 | $ (72,742) | 368,571 | $ 16,509 | (8,407) |
Balance at end of period, Treasury stock (in shares) at Dec. 31, 2021 | (9,894,000) | (9,894,000) | |||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||||
Accounting Standards Update [Extensible Enumeration] | Accounting Standards Update 2020-06 [Member] | ||||||||
Balance at beginning of period (in shares) at Mar. 31, 2021 | 53,065,000 | ||||||||
Balance at beginning of period at Mar. 31, 2021 | $ 1,011,011 | $ 53 | $ (238,109) | 950,361 | 304,849 | (6,143) | |||
Balance at beginning of period, Treasury stock (in shares) at Mar. 31, 2021 | (9,894,000) | ||||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||||
Net income | 20,424 | 20,424 | |||||||
Other comprehensive income (loss) | 652 | 652 | |||||||
Share-based compensation | 13,039 | 13,039 | |||||||
Issuance of common stock under employee stock plans (in shares) | 265,000 | ||||||||
Issuance of common stock under employee stock plans | 11,517 | 11,517 | |||||||
Tax payments related to restricted stock units | (4,071) | (4,071) | |||||||
Balance at end of period (in shares) at Jun. 30, 2021 | 53,330,000 | ||||||||
Balance at end of period at Jun. 30, 2021 | 1,052,572 | $ 53 | $ (238,109) | 970,846 | 325,273 | (5,491) | |||
Balance at end of period, Treasury stock (in shares) at Jun. 30, 2021 | (9,894,000) | ||||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||||
Net income | 29,317 | 29,317 | |||||||
Other comprehensive income (loss) | (2,299) | (2,299) | |||||||
Share-based compensation | 13,666 | 13,666 | |||||||
Issuance of common stock under employee stock plans (in shares) | 433,000 | ||||||||
Issuance of common stock under employee stock plans | 21,574 | $ 1 | 21,573 | ||||||
Tax payments related to restricted stock units | (3,494) | (3,494) | |||||||
Balance at end of period (in shares) at Sep. 30, 2021 | 53,763,000 | ||||||||
Balance at end of period at Sep. 30, 2021 | $ 1,111,336 | $ 54 | $ (238,109) | 1,002,591 | 354,590 | (7,790) | |||
Balance at end of period, Treasury stock (in shares) at Sep. 30, 2021 | (9,894,000) | ||||||||
Balance at beginning of period (in shares) at Dec. 31, 2021 | 44,179,000 | 54,073,000 | |||||||
Balance at beginning of period at Dec. 31, 2021 | $ 1,146,689 | (56,233) | $ 54 | $ (238,109) | 1,024,580 | (72,742) | 368,571 | 16,509 | (8,407) |
Balance at beginning of period, Treasury stock (in shares) at Dec. 31, 2021 | (9,894,000) | (9,894,000) | |||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||||
Net income | $ 8,213 | 8,213 | |||||||
Other comprehensive income (loss) | (2,555) | (2,555) | |||||||
Share-based compensation | 16,208 | 16,208 | |||||||
Issuance of common stock under employee stock plans (in shares) | 384,000 | ||||||||
Issuance of common stock under employee stock plans | 18,951 | 18,951 | |||||||
Tax payments related to restricted stock units | (4,322) | (4,322) | |||||||
Stock repurchases (in shares) | (389,000) | ||||||||
Stock repurchases | (52,210) | $ (52,210) | |||||||
Balance at end of period (in shares) at Mar. 31, 2022 | 54,457,000 | ||||||||
Balance at end of period at Mar. 31, 2022 | $ 1,074,741 | $ 54 | $ (290,319) | 982,675 | 393,293 | (10,962) | |||
Balance at end of period, Treasury stock (in shares) at Mar. 31, 2022 | (10,283,000) | ||||||||
Balance at beginning of period (in shares) at Dec. 31, 2021 | 44,179,000 | 54,073,000 | |||||||
Balance at beginning of period at Dec. 31, 2021 | $ 1,146,689 | $ (56,233) | $ 54 | $ (238,109) | 1,024,580 | $ (72,742) | 368,571 | $ 16,509 | (8,407) |
Balance at beginning of period, Treasury stock (in shares) at Dec. 31, 2021 | (9,894,000) | (9,894,000) | |||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||||
Net income | $ 34,056 | ||||||||
Other comprehensive income (loss) | $ (15,735) | ||||||||
Balance at end of period (in shares) at Sep. 30, 2022 | 44,646,000 | 54,929,000 | |||||||
Balance at end of period at Sep. 30, 2022 | $ 1,135,395 | $ 55 | $ (290,319) | 1,030,665 | 419,136 | (24,142) | |||
Balance at end of period, Treasury stock (in shares) at Sep. 30, 2022 | (10,283,000) | (10,283,000) | |||||||
Balance at beginning of period (in shares) at Mar. 31, 2022 | 54,457,000 | ||||||||
Balance at beginning of period at Mar. 31, 2022 | $ 1,074,741 | $ 54 | $ (290,319) | 982,675 | 393,293 | (10,962) | |||
Balance at beginning of period, Treasury stock (in shares) at Mar. 31, 2022 | (10,283,000) | ||||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||||
Net income | 9,069 | 9,069 | |||||||
Other comprehensive income (loss) | (6,410) | (6,410) | |||||||
Share-based compensation | 17,213 | 17,213 | |||||||
Issuance of common stock under employee stock plans (in shares) | 114,000 | ||||||||
Issuance of common stock under employee stock plans | 2,172 | $ 1 | 2,171 | ||||||
Tax payments related to restricted stock units | (4,148) | (4,148) | |||||||
Balance at end of period (in shares) at Jun. 30, 2022 | 54,571,000 | ||||||||
Balance at end of period at Jun. 30, 2022 | 1,092,637 | $ 55 | $ (290,319) | 997,911 | 402,362 | (17,372) | |||
Balance at end of period, Treasury stock (in shares) at Jun. 30, 2022 | (10,283,000) | ||||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||||
Net income | 16,774 | 16,774 | |||||||
Other comprehensive income (loss) | (6,770) | (6,770) | |||||||
Share-based compensation | 17,310 | 17,310 | |||||||
Issuance of common stock under employee stock plans (in shares) | 358,000 | ||||||||
Issuance of common stock under employee stock plans | 18,416 | 18,416 | |||||||
Tax payments related to restricted stock units | $ (2,972) | (2,972) | |||||||
Balance at end of period (in shares) at Sep. 30, 2022 | 44,646,000 | 54,929,000 | |||||||
Balance at end of period at Sep. 30, 2022 | $ 1,135,395 | $ 55 | $ (290,319) | $ 1,030,665 | $ 419,136 | $ (24,142) | |||
Balance at end of period, Treasury stock (in shares) at Sep. 30, 2022 | (10,283,000) | (10,283,000) |
Condensed Consolidated Statem_4
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands | 9 Months Ended | |
Sep. 30, 2022 | Sep. 30, 2021 | |
Operating Activities | ||
Net income | $ 34,056 | $ 63,868 |
Adjustments to reconcile net income to net cash provided by (used in) operating activities: | ||
Depreciation and amortization | 64,843 | 53,140 |
Loss on disposal of property and equipment | 331 | 297 |
Share-based compensation expense | 50,731 | 38,477 |
Deferred income taxes | (17,061) | 2,042 |
Amortization of operating lease right-of-use assets | 9,709 | 8,764 |
Impairment and abandonment of operating lease right-of-use assets related to facilities | 5,390 | 0 |
Amortization of debt issuance costs | 3,121 | 2,570 |
Amortization of discount on convertible senior notes | 0 | 13,874 |
Changes in operating assets and liabilities: | ||
Accounts receivable and unbilled receivables | (116,895) | (39,561) |
Inventories | (32,269) | (10,138) |
Prepaid expenses | (2,602) | (8,229) |
Other current assets | 6,692 | (1,059) |
Investment in sales-type leases | (17,336) | 2,686 |
Prepaid commissions | 8,801 | (1,030) |
Other long-term assets | 4,189 | 2,567 |
Accounts payable | 2,043 | 33,111 |
Accrued compensation | (27,940) | (12,018) |
Accrued liabilities | 11,678 | 20,149 |
Deferred revenues | 17,667 | 21,225 |
Operating lease liabilities | (10,966) | (9,392) |
Other long-term liabilities | 1,446 | (9,166) |
Net cash provided by (used in) operating activities | (4,372) | 172,177 |
Investing Activities | ||
Software development for external use | (9,648) | (24,141) |
Purchases of property and equipment | (33,861) | (17,892) |
Business acquisitions, net of cash acquired | (3,392) | (178,080) |
Purchase price adjustments from business acquisitions | 5,484 | 0 |
Net cash used in investing activities | (41,417) | (220,113) |
Financing Activities | ||
Proceeds from issuances under stock-based compensation plans | 39,539 | 53,917 |
Employees’ taxes paid related to restricted stock units | (11,442) | (10,161) |
Change in customer funds, net | (402) | (3,059) |
Stock repurchases | (52,210) | 0 |
Net cash provided by (used in) financing activities | (24,515) | 40,697 |
Effect of exchange rate changes on cash and cash equivalents | (1,425) | (492) |
Net decrease in cash, cash equivalents, and restricted cash | (71,729) | (7,731) |
Cash, cash equivalents, and restricted cash at beginning of period | 355,620 | 489,920 |
Cash, cash equivalents, and restricted cash at end of period | 283,891 | 482,189 |
Reconciliation of cash, cash equivalents, and restricted cash to the Condensed Consolidated Balance Sheets: | ||
Cash and cash equivalents | 266,402 | 481,549 |
Restricted cash included in other current assets | 17,489 | 640 |
Cash, cash equivalents, and restricted cash at end of period | 283,891 | 482,189 |
Supplemental disclosure of non-cash activities | ||
Unpaid purchases of property and equipment | 1,473 | 691 |
Transfers between inventory and property and equipment, net | $ 314 | $ 1,876 |
Organization and Summary of Sig
Organization and Summary of Significant Accounting Policies | 9 Months Ended |
Sep. 30, 2022 | |
Accounting Policies [Abstract] | |
Organization and Summary of Significant Accounting Policies | Organization and Summary of Significant Accounting Policies Business Omnicell, Inc. was incorporated in California in 1992 under the name Omnicell Technologies, Inc. and reincorporated in Delaware in 2001 as Omnicell, Inc. The Company’s major products and related services are medication management solutions and adherence tools for healthcare systems and pharmacies, which are sold in its principal market, the healthcare industry. The Company’s market is primarily located in the United States and Europe. “Omnicell” or the “Company” refer to Omnicell, Inc. and its subsidiaries, collectively. Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements reflect, in the opinion of management, all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the financial position of the Company as of September 30, 2022 and December 31, 2021, the results of operations and comprehensive income for the three and nine months ended September 30, 2022 and 2021, and cash flows for the nine months ended September 30, 2022 and 2021. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) have been condensed or omitted in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). These unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and accompanying Notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on February 25, 2022, except as discussed in the section entitled “Recently Adopted Authoritative Guidance” below. The Company’s results of operations and comprehensive income for the three and nine months ended September 30, 2022, and cash flows for the nine months ended September 30, 2022 are not necessarily indicative of results that may be expected for the year ending December 31, 2022, or for any future period. Principles of Consolidation The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. On January 10, 2022, the Company completed its acquisition of Hub and Spoke Innovations Limited (“Hub and Spoke Innovations”). The Condensed Consolidated Financial Statements include the results of operations of this recently acquired company, commencing as of the acquisition date. The significant accounting policies of the acquired business have been aligned to conform to the accounting policies of Omnicell. Use of Estimates The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company’s Condensed Consolidated Financial Statements and accompanying Notes. These estimates are based on historical experience and various other assumptions that management believes to be reasonable. Although these estimates are based on management’s best knowledge of current events and actions that may impact the Company in the future, actual results may be different from the estimates. The Company’s critical accounting policies are those that affect its financial statements materially and involve difficult, subjective, or complex judgments by management. As of September 30, 2022, the Company is not aware of any events or circumstances that would require an update to its estimates, judgments, or revisions to the carrying value of its assets or liabilities. Segment Reporting The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company’s Chief Operating Decision Maker (“CODM”) is its Chief Executive Officer. The CODM allocates resources and evaluates the performance of the Company at the consolidated level using information about its revenues, gross profit, income from operations, and other key financial data. All significant operating decisions are based upon an analysis of the Company as one operating segment, which is the same as its reporting segment. Recently Adopted Authoritative Guidance In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06 Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40) . The update simplifies the accounting for convertible debt instruments by reducing the number of accounting models and the number of embedded conversion features that could be recognized separately from the primary contract. ASU 2020-06 also enhances transparency and improves disclosures for convertible instruments and earnings per share guidance. ASU 2020-06 also requires the application of the if-converted method for calculating diluted earnings per share and the treasury stock method is no longer permitted for convertible instruments. This update permits the use of either the modified retrospective or fully retrospective method of transition. The Company adopted ASU 2020-06 on January 1, 2022, using the modified retrospective method of transition. Upon adoption of ASU 2020-06, the previously separated equity component and associated debt issuance costs for the Company’s outstanding convertible senior notes were reclassified to the liability component, thereby eliminating the subsequent amortization of the debt discount as interest expense. In addition, the Company derecognized the deferred tax liability related to the equity component. In December 2021, the Company made an irrevocable election under the indenture to require the principal portion of the Company’s convertible senior notes to be settled in cash and any conversion consideration in excess of the principal portion in cash and/or shares of the Company’s common stock at the Company’s option upon conversion. Following the irrevocable election, only the amounts expected to be settled in excess of the principal portion are considered dilutive in calculating earnings per share under the if-converted method. The Company’s adoption of the update impacted the Condensed Consolidated Balance Sheets at the beginning of the period of adoption as follows: January 1, 2022 Pre-ASU 2020-06 Balances ASU 2020-06 Adoption Impact Post-ASU 2020-06 Balances (In thousands) Long-term deferred tax assets $ 15,883 $ (452) $ 15,431 Convertible senior notes, net 488,152 75,353 563,505 Long-term deferred tax liabilities 51,705 (19,572) 32,133 Additional paid-in capital 1,024,580 (72,742) 951,838 Retained earnings 368,571 16,509 385,080 Adoption of the update did not have an impact on the Company’s Condensed Consolidated Statements of Operations or Condensed Consolidated Statements of Cash Flows as of January 1, 2022. Refer to Note 10, Convertible Senior Notes, for further information regarding the Company’s convertible senior notes. Recently Issued Authoritative Guidance In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers . The update addresses diversity in practice by requiring that an acquirer recognize and measure contract assets and liabilities acquired in a business combination in accordance with Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers. The guidance will be applied prospectively to acquisitions occurring on or after the effective date. ASU 2021-08 will be effective for the Company beginning January 1, 2023, and early adoption is permitted. The Company is currently evaluating the impact ASU 2021-08 will have on its Condensed Consolidated Financial Statements. No other recently issued and effective authoritative guidance is expected to have a material impact on the Company’s Condensed Consolidated Financial Statements through the reporting date. |
Business Combinations
Business Combinations | 9 Months Ended |
Sep. 30, 2022 | |
Business Combination and Asset Acquisition [Abstract] | |
Business Combinations | Business Combinations The Company accounted for its acquisitions in accordance with ASC 805, Business Combinations . The tangible and intangible assets acquired and liabilities assumed were recorded at fair value on the respective acquisition dates. Intangible assets eligible for recognition separate from goodwill were those that satisfied either the contractual or legal criterion or the separability criterion, each as set forth in the accounting guidance. The preliminary fair values reflect management’s best estimates based on information available at the respective acquisition dates and may change as additional information is received over the measurement period, which will end no later than one year from the respective acquisition date. The Company believes that the fair values assigned to the assets acquired and liabilities assumed are based on reasonable assumptions and estimates that market participants would use. Actual results may differ from these estimates and assumptions. The Company’s Condensed Consolidated Financial Statements include the results of operations of each acquired company, commencing as of their respective acquisition dates. Acquisition-related costs were expensed as incurred, and are included in selling, general, and administrative expenses in the Company’s Condensed Consolidated Statements of Operations. 2022 Acquisition Hub and Spoke Innovations On January 10, 2022, the Company completed the acquisition of all of the outstanding equity interests in Hub and Spoke Innovations, pursuant to the terms and conditions of the Share Purchase Agreement, dated January 10, 2022, by and among Omnicell Limited (a wholly-owned subsidiary of the Company), Hub and Spoke Innovations Limited, and certain beneficial stockholders specified therein for a base purchase price of £2.5 million (approximately $3.4 million based on the exchange rate in effect at the acquisition date), prior to customary adjustments for closing cash, net working capital, and assumed indebtedness. The preliminary purchase price transferred for the transaction, net of cash acquired, was £2.5 million (approximately $3.4 million based on the exchange rate in effect at the acquisition date). Of the purchase price transferred, £1.9 million (approximately $2.5 million based on the exchange rate in effect at the acquisition date) was allocated to goodwill; £0.8 million (approximately $1.1 million based on the exchange rate in effect at the acquisition date) was allocated to intangible assets, which included customer relationships; and the remainder was allocated to net assets acquired. The Hub and Spoke Innovations acquisition is expected to complement Omnicell’s total solution technology portfolio for retail pharmacy in the United Kingdom to help pharmacies improve workflows, offer patients 24/7 access to their medications and provide enhanced patient care. 2021 Acquisitions MarkeTouch Media On December 31, 2021, the Company completed the acquisition of all of the outstanding equity interests in MarkeTouch Media, LLC (“MarkeTouch Media”) pursuant to the terms and conditions of the Unit Purchase Agreement, dated December 31, 2021, by and among ateb, Inc. (a wholly-owned subsidiary of the Company), MarkeTouch Media, LLC, MarkeTouch Holdings, Inc., Toucan Enterprises, Inc., and certain beneficial stockholders specified therein for a base purchase price of $82.0 million, prior to customary adjustments for closing cash, net working capital, and assumed indebtedness. The MarkeTouch Media acquisition adds mobile and web-based technology and patient engagement solutions, which is expected to expand the footprint of EnlivenHealth ® across the retail pharmacy sector, while enhancing potential growth opportunities in new market segments like specialty pharmacy and pharmacy benefits management. ReCept On December 29, 2021, the Company completed the acquisition of all outstanding equity securities of ReCept Holdings, Inc. (“ReCept”) pursuant to the terms and conditions of the Agreement and Plan of Merger, dated December 1, 2021, by and among Omnicell, Inc., ReCept Holdings, Inc., Redfish Acquisition Corp, and the representative of the securityholders for a base purchase price of $100.0 million, prior to customary adjustments for closing cash, net working capital, and assumed indebtedness. The addition of ReCept’s specialty pharmacy management services, now a part of the Company’s Specialty Pharmacy Services (“Specialty Pharmacy Services”), for health systems, provider groups, and federally qualified health centers expands Omnicell’s Advanced Services portfolio in an effort to address the growing and complex specialty pharmacy market. FDS Amplicare On September 9, 2021, the Company completed the acquisition of all of the outstanding equity interests in RxInnovation, Inc., operating as FDS Amplicare (“FDS Amplicare”), pursuant to the terms and conditions of the Agreement and Plan of Merger, dated July 25, 2021, by and among RxInnovation Inc., Omnicell, Inc., Fleming Acquisition Corp., and the representative of the securityholders for a base purchase price of $177.0 million, prior to customary adjustments for closing cash, net working capital, and assumed indebtedness. The FDS Amplicare ® acquisition adds a comprehensive and complementary suite of Software-as-a-Service (“SaaS”) financial management, analytics, and population health solutions to the Company’s EnlivenHealth offering. The following tables represent the preliminary allocation of the respective purchase price to the assets acquired and the liabilities assumed by the Company as part of each acquisition included in the Company’s Consolidated Balance Sheets, and is reconciled to the respective purchase price transferred: FDS Amplicare (1) ReCept (2) (3) MarkeTouch Media (4) (In thousands) Purchase price transferred: Base purchase price $ 177,000 $ 100,000 $ 82,000 Add: Closing cash 465 6,569 237 Add: Net working capital adjustment 1,654 (7,357) 147 Less: Assumed indebtedness (653) (1,973) (15) Total purchase price transferred $ 178,466 $ 97,239 $ 82,369 FDS Amplicare (1) ReCept (Preliminary) (2) (3) MarkeTouch Media (Preliminary) (4) Fair value of assets acquired and liabilities assumed: Cash and cash equivalents $ 465 $ — $ 237 Accounts receivable and unbilled receivables 5,330 2,383 2,302 Prepaid expenses 506 192 96 Other current assets 45 12,223 — Total current assets 6,346 14,798 2,635 Property and equipment 444 172 177 Operating lease right-of-use assets 2,252 773 602 Goodwill 117,784 77,394 42,273 Intangible assets 70,000 28,100 38,000 Other long-term assets 51 195 2,850 Total assets 196,877 121,432 86,537 Accounts payable 950 219 473 Accrued compensation 1,312 1,756 — Accrued liabilities 1,497 18,499 292 Deferred revenues 1,916 222 347 Long-term deferred tax liabilities 11,686 2,883 — Long-term operating lease liabilities 920 614 206 Other long-term liabilities 130 — 2,850 Total liabilities 18,411 24,193 4,168 Total purchase price $ 178,466 $ 97,239 $ 82,369 Total purchase price, net of cash acquired $ 178,001 $ 90,670 $ 82,132 _________________________________________________ (1) During the fourth quarter of 2021, the Company recorded measurement period adjustments of $1.5 million to goodwill, consisting of an increase in intangible assets, accounts receivable and unbilled receivables, and long-term deferred tax liabilities of $0.4 million, $1.1 million, and $0.1 million, respectively, and a net working capital adjustment of $0.1 million. During the nine months ended September 30, 2022, the Company recorded a measurement period adjustments of $0.4 million to goodwill, consisting of an increase in long-term deferred tax liabilities and accrued liabilities of $0.3 million and $0.1 million, respectively. (2) Closing cash is included in other current assets due to its restrictive nature as cash held for customers. (3) During the nine months ended September 30, 2022, the Company recorded measurement period adjustments of $4.2 million to goodwill, consisting of a purchase price adjustment of $5.2 million and a decrease in long-term deferred tax liabilities of $0.7 million, partially offset by a decrease to other current assets of $1.7 million. (4) During the second quarter of 2022, the Company recorded a measurement period adjustment of $0.3 million to goodwill related to a purchase price adjustment. The $117.8 million of goodwill arising from the FDS Amplicare acquisition is primarily attributed to future sales of SaaS solutions and FDS Amplicare’s assembled workforce. The $77.4 million of goodwill arising from the ReCept acquisition is primarily attributed to future sales of its offerings and services and ReCept’s assembled workforce. None of the FDS Amplicare and ReCept goodwill is expected to be deductible for tax purposes as these acquisitions were treated as stock acquisitions for U.S. tax purposes. The $42.3 million of goodwill arising from the MarkeTouch Media acquisition is primarily attributed to future sales of SaaS solutions and MarkeTouch Media’s assembled workforce. The full amount of the MarkeTouch Media goodwill is expected to be deductible for tax purposes as this acquisition was treated as an asset acquisition for U.S. tax purposes. The identifiable intangible assets acquired and their estimated useful lives for amortization are as follows: FDS Amplicare (1) ReCept MarkeTouch Media Fair value Useful life Fair value Useful life Fair value Useful life (In thousands, except for years) Customer relationships $ 59,900 23 $ 28,100 23 $ 34,100 26 Acquired technology 7,700 5 - 7 — — 2,100 4 Backlog — — — — 1,800 2 Trade names 2,400 5 — — — — Total purchased intangible assets $ 70,000 $ 28,100 $ 38,000 _________________________________________________ (1) During the fourth quarter of 2021, the Company recorded a measurement period adjustment of $0.4 million in customer relationships. The customer relationships intangible assets represent the fair values of the underlying relationships and agreements with each acquired company’s customers. The acquired technology intangible assets represent the fair values of the portfolio of SaaS solutions that have reached technological feasibility and were part of the respective acquired company’s offerings at their respective acquisition dates. The backlog intangible asset represents contractually committed future billings associated with MarkeTouch Media customer contracts. The trade names intangible asset represents the fair value of brand and name recognition associated with the marketing of certain FDS Amplicare SaaS solutions. The fair values of the customer relationships and backlog intangible assets were determined based on the excess earnings method, and the fair values of the acquired technology and trade names intangible assets were determined based on the relief-from-royalty method. The key assumptions used in estimating the fair values of intangible assets included forecasted financial information; customer attrition rates; royalty rate of 10.0% for the acquired technology intangible assets for both FDS Amplicare and MarkeTouch Media; royalty rate of 2.0% for the FDS Amplicare trade names intangible asset; discount rate of 13.0% for the FDS Amplicare acquisition; discount rate of 15.0% for the ReCept acquisition; discount rate of 11.5% for the MarkeTouch Media acquisition; and certain other assumptions. The customer relationships and acquired technology intangible assets are being amortized using a double-declining method of amortization as such method better represents the economic benefits to be obtained. The backlog and trade names intangible assets are being amortized over their respective estimated useful lives using the straight-line method of amortization. Pro Forma Financial Information The following table presents certain unaudited pro forma consolidated financial information for the three and nine months ended September 30, 2021 as if the FDS Amplicare, ReCept, and MarkeTouch Media acquisitions had been completed on January 1, 2020. The pro forma effects of the Hub and Spoke Innovations acquisition were not material to the Company’s consolidated results of operations. The unaudited pro forma financial information is presented for informational purposes only, and is not indicative of what would have occurred had the acquisitions taken place on those respective dates. The unaudited pro forma financial information combines the historical results of the acquisitions with the Company’s consolidated historical results and includes certain adjustments including, but not limited to, amortization and depreciation of intangible assets and property and equipment acquired; and certain acquisition-related costs incurred. Three Months Ended September 30, Nine Months Ended September 30, 2021 2021 (In thousands) Pro forma revenues $ 313,170 $ 873,061 Pro forma net income $ 31,157 $ 65,050 |
Revenues
Revenues | 9 Months Ended |
Sep. 30, 2022 | |
Revenue Recognition [Abstract] | |
Revenues | Revenues Revenue Recognition The Company earns revenues from sales of its products and related services, which are sold in the healthcare industry, its principal market. The Company’s customer arrangements typically include one or more of the following revenue categories: Connected devices, software licenses, and other. Software-enabled connected devices and software licenses that manage and regulate the storage and dispensing of pharmaceuticals, consumables blister cards, and packaging equipment and other supplies. This revenue category is often sold through long-term, sole-source agreements with multi-year co-development plans. Solutions in this category include, but are not limited to, XT Series automated dispensing systems, the XR2 Automated Central Pharmacy System, IVX Station and IV compounding automation solutions. Technical services. Post-installation technical support and other related services, including phone support, on-site service, parts, and access to unspecified software updates and enhancements, if and when available. This revenue category is often supported by multi-year or annual contractual agreements. Consumables. Medication adherence packaging, labeling, and other one-time use packaging including multimed adherence packaging and single dose blister cards which are used by retail, community, and outpatient pharmacies, as well as by institutional pharmacies serving long-term care and other sites outside the acute care hospital, and are designed to improve patient engagement and adherence to prescriptions. SaaS, subscription software, and technology-enabled services. Emerging software and service solutions which are offered on a subscription basis with fees typically based either on transaction volume or a fee over a specified period of time. Solutions in this category include, but are not limited to, EnlivenHealth inclusive of FDS Amplicare and MarkeTouch Media, 340B solutions, Specialty Pharmacy Services, and services associated with Omnicell One™, Central Pharmacy Dispensing Services, including the XR2 Automated Central Pharmacy System, and Central Pharmacy Compounding Services, including IVX Station and IV compounding automation solutions. The following table summarizes revenue recognition for each revenue category: Revenue Category Timing of Revenue Recognition Income Statement Classification Connected devices, software licenses, and other Point in time, as transfer of control occurs, generally upon installation and acceptance by the customer Product Technical services Over time, as services are provided, typically ratably over the service term Service Consumables Point in time, as transfer of control occurs, generally upon shipment to or receipt by customer Product SaaS, subscription software, and technology-enabled services Over time, as services are provided Service A portion of the Company’s sales are made to customers who are members of Group Purchasing Organizations (“GPOs”) and Federal agencies that purchase under a Federal Supply Schedule Contract with the Department of Veterans Affairs (the “GSA Contract”). GPOs are often fully or partially owned by the Company’s customers, and the Company pays fees to the GPO on completed contracts. The Company also pays the Industrial Funding Fee (“IFF”) to the Department of Veterans Affairs under the GSA Contract. The Company considers these fees consideration paid to customers and records them as reductions to revenue. Fees to GPOs and the IFF were $4.8 million and $4.4 million for the three months ended September 30, 2022 and 2021, respectively, and $13.3 million and $12.0 million for the nine months ended September 30, 2022 and 2021, respectively. Disaggregation of Revenues The following table summarizes the Company’s revenues disaggregated by revenue type for the three and nine months ended September 30, 2022 and 2021: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 (In thousands) Connected devices, software licenses, and other $ 226,415 $ 195,820 $ 650,125 $ 534,582 Technical services 53,914 53,529 156,386 156,321 Consumables 20,150 18,150 56,121 54,424 SaaS, subscription software, and technology-enabled services 47,580 28,903 135,641 75,657 Total revenues $ 348,059 $ 296,402 $ 998,273 $ 820,984 The following table summarizes the Company’s revenues disaggregated by geographic region, which is determined based on customer location, for the three and nine months ended September 30, 2022 and 2021: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 (In thousands) United States $ 315,755 $ 271,276 $ 898,269 $ 738,411 Rest of world (1) 32,304 25,126 100,004 82,573 Total revenues $ 348,059 $ 296,402 $ 998,273 $ 820,984 _________________________________________________ (1) No individual country represented more than 10% of total revenues. Contract Assets and Contract Liabilities The following table reflects the Company’s contract assets and contract liabilities: September 30, December 31, (In thousands) Short-term unbilled receivables, net (1) $ 28,354 $ 17,208 Long-term unbilled receivables, net (2) 13,815 18,084 Total contract assets $ 42,169 $ 35,292 Short-term deferred revenues, net $ 113,925 $ 112,196 Long-term deferred revenues 34,519 20,194 Total contract liabilities $ 148,444 $ 132,390 _________________________________________________ (1) Included in accounts receivable and unbilled receivables in the Condensed Consolidated Balance Sheets. (2) Included in other long-term assets in the Condensed Consolidated Balance Sheets. The portion of the transaction price allocated to the Company’s unsatisfied performance obligations for which invoicing has occurred is recorded as deferred revenues. Short-term deferred revenues of $113.9 million and $112.2 million include deferred revenues from product sales and service contracts, net of deferred cost of sales of $12.5 million and $22.4 million, as of September 30, 2022 and December 31, 2021, respectively. The short-term deferred revenues from product sales relate to delivered and invoiced products, pending installation and acceptance, expected to occur within the next twelve months. During the three and nine months ended September 30, 2022, the Company recognized revenues of $15.2 million and $104.2 million, respectively, that were included in the corresponding gross short-term deferred revenues balance of $134.6 million as of December 31, 2021. Long-term deferred revenues include deferred revenues from product and service contracts of $34.5 million and $20.2 million as of September 30, 2022 and December 31, 2021, respectively. Remaining performance obligations are primarily recognized ratably over the remaining term of the contract, generally not more than ten years. Significant Customers There were no customers that accounted for more than 10% of the Company’s total revenues for the three and nine months ended September 30, 2022 and 2021. Also, there were no customers that accounted for more than 10% of the Company’s accounts receivable balance as of September 30, 2022 and December 31, 2021. |
Net Income Per Share
Net Income Per Share | 9 Months Ended |
Sep. 30, 2022 | |
Earnings Per Share [Abstract] | |
Net Income Per Share | Net Income Per Share Basic net income (loss) per share is computed by dividing net income (loss) for the period by the weighted-average number of shares outstanding during the period. In periods of net loss, all potential common shares are anti-dilutive, so diluted net loss per share equals the basic net loss per share. In periods of net income, diluted net income per share is computed by dividing net income for the period by the basic weighted-average number of shares plus any dilutive potential common stock outstanding during the period, using the treasury stock method. Potential common stock includes the effect of outstanding dilutive stock options, restricted stock awards, and restricted stock units, as well as shares the Company could be obligated to issue from its convertible senior notes and warrants, as described in Note 10, Convertible Senior Notes (pre-ASU 2020-06 adoption). For periods prior to the adoption of ASU 2020-06 on January 1, 2022, the Company applied the treasury stock method to calculate the dilutive impact of the convertible senior notes. Upon adoption of ASU 2020-06, effective January 1, 2022, the Company is required to apply the if-converted method for calculating the dilutive impact of the convertible senior notes. Refer to Note 1, Organization and Summary of Significant Accounting Policies , for further information. Any anti-dilutive weighted-average dilutive shares related to stock award plans, convertible senior notes, and warrants are excluded from the computation of the diluted net income per share. The basic and diluted net income per share calculations for the three and nine months ended September 30, 2022 and 2021 were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 (In thousands, except per share data) Net income $ 16,774 $ 29,317 $ 34,056 $ 63,868 Weighted-average shares outstanding – basic 44,441 43,648 44,304 43,293 Effect of dilutive securities from stock award plans 943 2,087 1,293 2,086 Effect of convertible senior notes 435 2,156 1,162 1,816 Effect of warrants — 450 — — Weighted-average shares outstanding – diluted 45,819 48,341 46,759 47,195 Net income per share – basic $ 0.38 $ 0.67 $ 0.77 $ 1.48 Net income per share – diluted $ 0.37 $ 0.61 $ 0.73 $ 1.35 Anti-dilutive weighted-average shares related to stock award plans 810 64 689 199 Anti-dilutive weighted-average shares related to convertible senior notes and warrants 5,908 — 5,908 5,908 |
Cash and Cash Equivalents and F
Cash and Cash Equivalents and Fair Value of Financial Instruments | 9 Months Ended |
Sep. 30, 2022 | |
Fair Value Disclosures [Abstract] | |
Cash and Cash Equivalents and Fair Value of Financial Instruments | Cash and Cash Equivalents and Fair Value of Financial Instruments Cash and cash equivalents of $266.4 million and $349.1 million as of September 30, 2022 and December 31, 2021, respectively, consisted of bank accounts and highly-liquid U.S. Government money market funds held in sweep and asset management accounts with major financial institutions. As of September 30, 2022 and December 31, 2021, cash equivalents were $224.7 million and $320.2 million, respectively, which consisted of money market funds held in sweep and asset management accounts. Fair Value Hierarchy The Company measures its financial instruments at fair value. The Company’s cash, cash equivalents, and restricted cash are classified within Level 1 of the fair value hierarchy as they are valued primarily using quoted market prices utilizing market observable inputs. The Company’s credit facility is classified within Level 2 as the valuation inputs are based on quoted prices or market observable data of similar instruments. The Company’s convertible senior notes are classified within Level 2 as the valuation inputs are based on quoted prices in an inactive market on the last day in the reporting period. As of September 30, 2022, the fair value of the convertible senior notes was $610.1 million, compared to their carrying value of $565.8 million, which is net of unamortized debt issuance costs (subsequent to the adoption of ASU 2020-06). As of December 31, 2021, the fair value of the convertible senior notes was $1.085 billion, compared to their carrying value of $488.2 million, which is net of unamortized discount and debt issuance costs and excludes amounts classified within additional paid-in capital (prior to the adoption of ASU 2020-06). Refer to Note 9, Debt and Credit Agreement, for further information regarding the Company’s credit facility and Note 10, Convertible Senior Notes, for further information regarding the Company’s convertible senior notes. Refer to Note 1, Organization and Summary of Significant Accounting Policies , for further information regarding the adoption of ASU 2020-06. |
Balance Sheet Components
Balance Sheet Components | 9 Months Ended |
Sep. 30, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Balance Sheet Components | Balance Sheet Components Balance sheet details as of September 30, 2022 and December 31, 2021 are presented in the tables below: September 30, December 31, (In thousands) Inventories: Raw materials $ 73,221 $ 48,215 Work in process 8,970 11,009 Finished goods 64,905 60,700 Total inventories $ 147,096 $ 119,924 Other current assets: Funds held for customers, including restricted cash (1) $ 35,249 $ 20,405 Net investment in sales-type leases, current portion 12,586 10,665 Prepaid income taxes 1,846 6,656 Other current assets 6,993 10,608 Total other current assets $ 56,674 $ 48,334 Other long-term assets: Capitalized software, net $ 85,186 $ 96,995 Unbilled receivables, net 13,815 18,084 Deferred debt issuance costs 2,333 3,156 Other long-term assets 9,012 9,284 Total other long-term assets $ 110,346 $ 127,519 Accrued liabilities: Operating lease liabilities, current portion $ 10,658 $ 12,947 Customer fund liabilities 35,249 31,727 Advance payments from customers 10,214 8,191 Rebate liabilities 42,363 44,644 Group purchasing organization fees 7,623 7,115 Taxes payable 11,327 3,771 Other accrued liabilities 29,006 24,772 Total accrued liabilities $ 146,440 $ 133,167 _________________________________________________ (1) Includes restricted cash of $17.5 million and $6.6 million as of September 30, 2022 and December 31, 2021, respectively. The following table summarizes the changes in accumulated balances of other comprehensive income (loss), which consisted of foreign currency translation adjustments, for the three and nine months ended September 30, 2022 and 2021: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 (In thousands) Beginning balance $ (17,372) $ (5,491) $ (8,407) $ (5,522) Other comprehensive loss (6,770) (2,299) (15,735) (2,268) Ending balance $ (24,142) $ (7,790) $ (24,142) $ (7,790) |
Property and Equipment
Property and Equipment | 9 Months Ended |
Sep. 30, 2022 | |
Property, Plant and Equipment [Abstract] | |
Property and Equipment | Property and Equipment The following table represents the property and equipment balances as of September 30, 2022 and December 31, 2021: September 30, December 31, (In thousands) Equipment $ 89,429 $ 89,272 Furniture and fixtures 5,026 7,580 Leasehold improvements 19,766 20,623 Software 73,913 60,856 Construction in progress 23,041 14,757 Property and equipment, gross 211,175 193,088 Accumulated depreciation and amortization (122,819) (121,947) Total property and equipment, net $ 88,356 $ 71,141 Depreciation and amortization expense of property and equipment was $5.8 million and $5.2 million for the three months ended September 30, 2022 and 2021, respectively, and $16.7 million and $14.9 million for the nine months ended September 30, 2022 and 2021, respectively. The geographic location of the Company’s property and equipment, net, is based on the physical location in which it is located. The following table summarizes the geographic information for property and equipment, net, as of September 30, 2022 and December 31, 2021: September 30, December 31, (In thousands) United States $ 84,771 $ 66,788 Rest of world (1) 3,585 4,353 Total property and equipment, net $ 88,356 $ 71,141 _________________________________________________ (1) No individual country represented more than 10% of total property and equipment, net. |
Goodwill and Intangible Assets
Goodwill and Intangible Assets | 9 Months Ended |
Sep. 30, 2022 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Goodwill and Intangible Assets | Goodwill and Intangible Assets Goodwill The following table represents changes in the carrying amount of goodwill: December 31, Additions (1) Measurement Period Adjustments (1) Foreign currency exchange rate fluctuations September 30, (In thousands) Goodwill $ 738,900 2,549 (4,041) (6,114) $ 731,294 _________________________________________________ (1) Refer to Note 2, Business Combinations, for further information. Intangible Assets, Net The carrying amounts and useful lives of intangible assets as of September 30, 2022 and December 31, 2021 were as follows: September 30, 2022 Gross carrying amount (1) Accumulated Foreign currency exchange rate fluctuations Net carrying Useful life (In thousands, except for years) Customer relationships $ 311,089 $ (94,108) $ (1,880) $ 215,101 4 - 30 Acquired technology 92,066 (61,471) — 30,595 4 - 20 Backlog 1,800 (675) — 1,125 2 Trade names 9,200 (6,371) — 2,829 5 - 12 Patents 2,430 (1,276) — 1,154 2 - 20 Non-compete agreements 600 (400) — 200 3 Total intangibles assets, net $ 417,185 $ (164,301) $ (1,880) $ 251,004 December 31, 2021 Gross carrying amount (1) Accumulated Foreign currency exchange rate fluctuations Net carrying Useful life (In thousands, except for years) Customer relationships $ 309,989 $ (78,093) $ (933) $ 230,963 10 - 30 Acquired technology 95,466 (55,859) 6 39,613 4 - 20 Backlog 1,800 — — 1,800 2 Trade names 9,200 (5,600) 14 3,614 5 - 12 Patents 2,462 (1,186) — 1,276 2 - 20 Non-compete agreements 600 (250) — 350 3 Total intangibles assets, net $ 419,517 $ (140,988) $ (913) $ 277,616 _________________________________________________ (1) The differences in gross carrying amounts between periods are primarily due to the write-off of certain fully amortized intangible assets, partially offset by additions of intangible assets in connection with the Hub and Spoke Innovations acquisition. Amortization expense of intangible assets was $8.7 million and $6.3 million for the three months ended September 30, 2022 and 2021, respectively, and $26.7 million and $18.7 million for the nine months ended September 30, 2022 and 2021, respectively. The estimated future amortization expenses for amortizable intangible assets were as follows: September 30, (In thousands) Remaining three months of 2022 $ 8,463 2023 31,463 2024 23,015 2025 20,970 2026 18,027 Thereafter 149,066 Total $ 251,004 |
Debt and Credit Agreement
Debt and Credit Agreement | 9 Months Ended |
Sep. 30, 2022 | |
Debt Disclosure [Abstract] | |
Debt and Credit Agreement | Debt and Credit Agreement 2019 Revolving Credit Facility On November 15, 2019, the Company entered into an Amended and Restated Credit Agreement (as subsequently amended as discussed below, the “A&R Credit Agreement”) with the lenders from time to time party thereto, Wells Fargo Securities, LLC, Citizens Bank, N.A., and JPMorgan Chase Bank, N.A., as joint lead arrangers, and Wells Fargo Bank, National Association, as administrative agent. The A&R Credit Agreement superseded the Company’s 2016 secured credit facility and provides for (a) a five-year revolving credit facility of $500.0 million (the “Revolving Credit Facility”) and (b) an uncommitted incremental loan facility of up to $250.0 million (the “Incremental Facility”). In addition, the A&R Credit Agreement includes a letter of credit sub-limit of up to $15.0 million and a swing line loan sub-limit of up to $25.0 million. The A&R Credit Agreement has an expiration date of November 15, 2024, upon which date all remaining outstanding borrowings will be due and payable. Loans under the Revolving Credit Facility bear interest, at the Company’s option, at a rate equal to either (a) the LIBOR Rate, plus an applicable margin ranging from 1.25% to 2.00% per annum based on the Company’s Consolidated Total Net Leverage Ratio (as defined in the A&R Credit Agreement), or (b) an alternate base rate equal to the highest of (i) the prime rate, (ii) the federal funds rate plus 0.50%, and (iii) LIBOR for an interest period of one month plus 1.00%, plus an applicable margin ranging from 0.25% to 1.00% per annum based on the Company’s Consolidated Total Net Leverage Ratio. Undrawn commitments under the Revolving Credit Facility are subject to a commitment fee ranging from 0.15% to 0.30% per annum based on the Company’s Consolidated Total Net Leverage Ratio on the average daily unused portion of the Revolving Credit Facility. The applicable margin for, and certain other terms of, any term loans under the Incremental Facility will be determined prior to the incurrence of such loans. The Company is permitted to make voluntary prepayments at any time without payment of a premium or penalty. On September 22, 2020, the parties entered into an amendment to the A&R Credit Agreement to, among other changes, permit the issuance of the convertible senior notes and the purchase of the convertible note hedge transactions, as described in Note 10, Convertible Senior Notes , expand the Company’s flexibility to repurchase its common stock and make other restricted payments, and replace the total net leverage covenant with a new secured net leverage covenant that requires the Company to maintain a consolidated secured net leverage ratio not to exceed 3.50:1 for the calendar quarters ending September 30, 2020, December 31, 2020, and March 31, 2021 and 3.00:1 for the calendar quarters ending thereafter. The A&R Credit Agreement contains customary representations and warranties and customary affirmative and negative covenants applicable to the Company and its subsidiaries, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, dividends, and other distributions. The A&R Credit Agreement contains financial covenants that require the Company and its subsidiaries to not exceed a maximum total secured net leverage ratio (as described above) and maintain a minimum interest coverage ratio. In addition, the A&R Credit Agreement contains certain customary events of default including, but not limited to, failure to pay interest, principal, and fees, or other amounts when due, material misrepresentations or misstatements in any representation or warranty, covenant defaults, certain cross defaults to other material indebtedness, certain judgment defaults, and events of bankruptcy. The Company’s obligations under the A&R Credit Agreement and any swap obligations and banking services obligations owing to a lender (or an affiliate of a lender) are guaranteed by certain of its domestic subsidiaries and secured by substantially all of its and such subsidiary guarantors’ assets. In connection with entering into the A&R Credit Agreement, and as a condition precedent to borrowing loans thereunder, the Company and certain of the Company’s other direct and indirect subsidiaries have entered into certain ancillary agreements, including, but not limited to, a reaffirmation agreement, which amends certain terms of the existing collateral agreement and reaffirms their obligations under the existing guaranty agreement. The Company was in compliance with all covenants as of September 30, 2022. As of each of September 30, 2022 and December 31, 2021, there was no outstanding balance for the Revolving Credit Facility. 0.25% Convertible Senior Notes due 2025 On September 25, 2020, the Company completed a private offering of $575.0 million aggregate principal amount of 0.25% convertible senior notes (the “Notes”), including the exercise in full of the initial purchasers’ option to purchase up to an additional $75.0 million principal amount of the Notes. The Company received proceeds from the issuance of the Notes of $559.7 million, net of $15.3 million of transaction fees and other debt issuance costs. The Notes bear interest at a rate of 0.25% per year, payable semiannually in arrears on March 15 and September 15 of each year, beginning on March 15, 2021. The Notes were issued pursuant to an indenture, dated September 25, 2020 (the “Indenture”), between the Company and U.S. Bank National Association, as trustee. The Notes are general senior, unsecured obligations of the Company and will mature on September 15, 2025, unless earlier redeemed, repurchased, or converted. The Notes are convertible at the option of the holders at any time prior to the close of business on the business day immediately preceding May 15, 2025, only under the following circumstances: (i) during any fiscal quarter commencing after the fiscal quarter ended on December 31, 2020 (and only during such fiscal quarter), if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding fiscal quarter is greater than or equal to 130% of the conversion price for the Notes on each applicable trading day; (ii) during the five business day period after any ten consecutive trading day period (the “measurement period”) in which the trading price (as defined in the Indenture) per $1,000 principal amount of the Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate for the Notes on each such trading day; (iii) if the Company calls such Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date, but only with respect to the Notes called (or deemed called) for redemption; and (iv) upon the occurrence of specified corporate events, as specified in the Indenture. On or after May 15, 2025 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders of the Notes may convert all or any portion of their Notes at any time, regardless of the foregoing conditions. During the three months ended December 31, 2021, the conditional conversion feature of the Notes was triggered, based on the price of the Company’s common stock, as the last reported sale price of the Company’s common stock was greater than or equal to 130% of the then applicable conversion price for the Notes for at least 20 trading days during the period of 30 consecutive trading days ending on December 31, 2021, the last trading day of the respective fiscal quarter. Accordingly, the Notes were convertible during the first quarter of 2022 and were classified as a current liability in the Consolidated Financial Statements as of December 31, 2021. During the three months ended September 30, 2022, none of the conditional conversion features of the Notes were triggered, and therefore, the Notes are not convertible during the fourth quarter of 2022, commencing on October 1, 2022. Accordingly, the Company classified the Notes as a long-term liability in its Condensed Consolidated Financial Statements as of September 30, 2022. Whether the Notes will be convertible following the fourth fiscal quarter of 2022 will depend on the satisfaction of the conversion conditions in the future. Under the original terms of the Indenture, upon conversion, the Company could satisfy its conversion obligation by paying or delivering cash, shares of its common stock, or a combination thereof, at the Company’s election, in the manner and subject to the terms and conditions provided in the Indenture. On December 13, 2021, the Company irrevocably elected to fix its settlement method to a combination of cash and shares of the Company’s common stock with the specified cash amount per $1,000 principal amount of Notes of at least $1,000. As a result, for Notes converted on or after December 13, 2021, a converting noteholder will receive (i) up to $1,000 in cash per $1,000 principal amount of Notes and (ii) cash and/or shares of the Company’s common stock, at the Company’s option for any conversion consideration in excess of $1,000. In addition, the Company continues to have the ability to set the specified cash amount per $1,000 principal amount of Notes above $1,000. The initial conversion rate for the Notes is 10.2751 shares of the Company’s common stock per $1,000 principal amount of Notes, which is equivalent to an initial conversion price of approximately $97.32 per share of the Company’s common stock, subject to adjustment under certain circumstances in accordance with the terms of the Indenture. In addition, following certain corporate events that could occur prior to the maturity date of the Notes or if the Company delivers a notice of redemption in respect of the Notes, the Company will, under certain circumstances, increase the conversion rate of the Notes for a holder who elects to convert its Notes (or any portion thereof) in connection with such a corporate event or convert its Notes called (or deemed called) for redemption during the related redemption period (as defined in the Indenture), as the case may be. If the Company undergoes a fundamental change, holders may require, subject to certain exceptions, the Company to repurchase for cash all or any portion of their Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. As of September 30, 2022, none of the criteria for a fundamental change or a conversion rate adjustment had been met. The Company may not redeem the Notes prior to September 20, 2023. The Company may redeem for cash all or any portion of the Notes, at its option, on or after September 20, 2023, if the last reported sale price of the Company’s common stock has been at least 130% of the conversion price for the Notes then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If the Company redeems less than all of the outstanding Notes, at least $150.0 million aggregate principal amount of Notes must be outstanding and not subject to redemption as of the date of the relevant notice of redemption. No sinking fund is provided for in the Notes. Prior to the adoption of ASU 2020-06, convertible debt instruments that could be settled in cash were required to be separated into liability and equity components. The allocation to the liability component was based on the fair value of a similar instrument that did not contain an equity conversion option. Based on this debt-to-equity ratio, debt issuance costs were then allocated to the liability and equity components in a similar manner. Accordingly, at issuance, the Company allocated $461.8 million to the debt liability and $72.7 million to additional paid-in capital, net of applicable issuance costs and deferred taxes. The difference between the principal amount of the Notes and the liability component, inclusive of issuance costs, represented the debt discount, which the Company amortized to interest expense over the term of the Notes using an effective interest rate of 4.18%. The determination of the discount rate required certain estimates and assumptions. Upon adoption of ASU 2020-06, effective January 1, 2022, the Notes are no longer separated into liability and equity components, and are accounted for as a single liability measured at its amortized cost. Refer to Note 1, Organization and Summary of Significant Accounting Policies , for further information. As of September 30, 2022, the remaining life of the Notes and the related issuance cost accretion is approximately 3.0 years. The maximum number of shares issuable upon conversion, including the effect of a fundamental change and subject to other conversion rate adjustments, would be 5.9 million shares. As of September 30, 2022, the if-converted value of the Notes did not exceed the principal amount. The Notes consisted of the following balances reported in the Condensed Consolidated Balance Sheets as of September 30, 2022 and December 31, 2021: September 30, 2022 (2) December 31, (In thousands) Liability: Principal amount $ 575,000 $ 575,000 Unamortized discount — (77,136) Unamortized debt issuance costs (9,197) (9,712) Convertible senior notes, liability component (1) $ 565,803 $ 488,152 Convertible senior notes, equity component $ — $ 72,732 _________________________________________________ (1) Classified as a long-term liability as of September 30, 2022, and a current liability as of December 31, 2021, in the Condensed Consolidated Balance Sheets. (2) Refer to Note 1, Organization and Summary of Significant Accounting Policies , for further information regarding the impact of the adoption of ASU 2020-06, effective January 1, 2022. The following table summarizes the components of interest expense resulting from the Notes recognized in interest and other income (expense), net in the Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2022 and 2021: Three Months Ended September 30, Nine Months Ended September 30, 2022 (1) 2021 2022 (1) 2021 (In thousands) Contractual coupon interest $ 359 $ 359 $ 1,078 $ 1,078 Amortization of discount $ — $ 4,679 $ — $ 13,874 Amortization of debt issuance costs $ 768 $ 589 $ 2,298 $ 1,747 _________________________________________________ (1) Refer to Note 1, Organization and Summary of Significant Accounting Policies , for further information regarding the impact of the adoption of ASU 2020-06, effective January 1, 2022. Convertible Note Hedge and Warrant Transactions In connection with the issuance of the Notes, the Company entered into convertible note hedge and warrant transactions with an affiliate of one of the initial purchasers of the Notes and certain other financial institutions (the “option counterparties”) with respect to the Company’s common stock. The convertible note hedge consists of an option for the Company to purchase up to approximately 5.9 million shares of the Company’s common stock, which is equal to the number of shares of the Company’s common stock underlying the Notes, at an initial strike price of approximately $97.32 per share. The convertible note hedge will expire upon the maturity of the Notes, if not earlier exercised or terminated. The cost of the convertible note hedge was approximately $100.6 million and was accounted for as an equity instrument, which was recorded in additional paid-in capital in the Condensed Consolidated Balance Sheets. The Company recorded a deferred tax asset of $25.8 million at issuance related to the convertible note hedge transaction. The convertible note hedge is expected generally to reduce the potential dilution to the Company’s common stock upon any conversion of Notes and/or offset any cash payments the Company is required to make in excess of the principal amount of converted Notes. Separately from the convertible note hedge, the Company entered into warrant transactions to sell to the option counterparties warrants to acquire, subject to customary anti-dilution adjustments, up to approximately 5.9 million shares of its common stock in the aggregate at an initial strike price of $141.56 per share. The warrants require net share or net cash settlement upon the Company’s election. The Company received aggregate proceeds of approximately $51.3 million for the issuance of the warrants, which was recorded in additional paid-in capital at issuance in the Condensed Consolidated Balance Sheets. The warrants could separately have a dilutive effect to the Company’s common stock to the extent that the market price per share of its common stock exceeds the strike price of the warrants. |
Convertible Senior Notes
Convertible Senior Notes | 9 Months Ended |
Sep. 30, 2022 | |
Debt Disclosure [Abstract] | |
Convertible Senior Notes | Debt and Credit Agreement 2019 Revolving Credit Facility On November 15, 2019, the Company entered into an Amended and Restated Credit Agreement (as subsequently amended as discussed below, the “A&R Credit Agreement”) with the lenders from time to time party thereto, Wells Fargo Securities, LLC, Citizens Bank, N.A., and JPMorgan Chase Bank, N.A., as joint lead arrangers, and Wells Fargo Bank, National Association, as administrative agent. The A&R Credit Agreement superseded the Company’s 2016 secured credit facility and provides for (a) a five-year revolving credit facility of $500.0 million (the “Revolving Credit Facility”) and (b) an uncommitted incremental loan facility of up to $250.0 million (the “Incremental Facility”). In addition, the A&R Credit Agreement includes a letter of credit sub-limit of up to $15.0 million and a swing line loan sub-limit of up to $25.0 million. The A&R Credit Agreement has an expiration date of November 15, 2024, upon which date all remaining outstanding borrowings will be due and payable. Loans under the Revolving Credit Facility bear interest, at the Company’s option, at a rate equal to either (a) the LIBOR Rate, plus an applicable margin ranging from 1.25% to 2.00% per annum based on the Company’s Consolidated Total Net Leverage Ratio (as defined in the A&R Credit Agreement), or (b) an alternate base rate equal to the highest of (i) the prime rate, (ii) the federal funds rate plus 0.50%, and (iii) LIBOR for an interest period of one month plus 1.00%, plus an applicable margin ranging from 0.25% to 1.00% per annum based on the Company’s Consolidated Total Net Leverage Ratio. Undrawn commitments under the Revolving Credit Facility are subject to a commitment fee ranging from 0.15% to 0.30% per annum based on the Company’s Consolidated Total Net Leverage Ratio on the average daily unused portion of the Revolving Credit Facility. The applicable margin for, and certain other terms of, any term loans under the Incremental Facility will be determined prior to the incurrence of such loans. The Company is permitted to make voluntary prepayments at any time without payment of a premium or penalty. On September 22, 2020, the parties entered into an amendment to the A&R Credit Agreement to, among other changes, permit the issuance of the convertible senior notes and the purchase of the convertible note hedge transactions, as described in Note 10, Convertible Senior Notes , expand the Company’s flexibility to repurchase its common stock and make other restricted payments, and replace the total net leverage covenant with a new secured net leverage covenant that requires the Company to maintain a consolidated secured net leverage ratio not to exceed 3.50:1 for the calendar quarters ending September 30, 2020, December 31, 2020, and March 31, 2021 and 3.00:1 for the calendar quarters ending thereafter. The A&R Credit Agreement contains customary representations and warranties and customary affirmative and negative covenants applicable to the Company and its subsidiaries, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, dividends, and other distributions. The A&R Credit Agreement contains financial covenants that require the Company and its subsidiaries to not exceed a maximum total secured net leverage ratio (as described above) and maintain a minimum interest coverage ratio. In addition, the A&R Credit Agreement contains certain customary events of default including, but not limited to, failure to pay interest, principal, and fees, or other amounts when due, material misrepresentations or misstatements in any representation or warranty, covenant defaults, certain cross defaults to other material indebtedness, certain judgment defaults, and events of bankruptcy. The Company’s obligations under the A&R Credit Agreement and any swap obligations and banking services obligations owing to a lender (or an affiliate of a lender) are guaranteed by certain of its domestic subsidiaries and secured by substantially all of its and such subsidiary guarantors’ assets. In connection with entering into the A&R Credit Agreement, and as a condition precedent to borrowing loans thereunder, the Company and certain of the Company’s other direct and indirect subsidiaries have entered into certain ancillary agreements, including, but not limited to, a reaffirmation agreement, which amends certain terms of the existing collateral agreement and reaffirms their obligations under the existing guaranty agreement. The Company was in compliance with all covenants as of September 30, 2022. As of each of September 30, 2022 and December 31, 2021, there was no outstanding balance for the Revolving Credit Facility. 0.25% Convertible Senior Notes due 2025 On September 25, 2020, the Company completed a private offering of $575.0 million aggregate principal amount of 0.25% convertible senior notes (the “Notes”), including the exercise in full of the initial purchasers’ option to purchase up to an additional $75.0 million principal amount of the Notes. The Company received proceeds from the issuance of the Notes of $559.7 million, net of $15.3 million of transaction fees and other debt issuance costs. The Notes bear interest at a rate of 0.25% per year, payable semiannually in arrears on March 15 and September 15 of each year, beginning on March 15, 2021. The Notes were issued pursuant to an indenture, dated September 25, 2020 (the “Indenture”), between the Company and U.S. Bank National Association, as trustee. The Notes are general senior, unsecured obligations of the Company and will mature on September 15, 2025, unless earlier redeemed, repurchased, or converted. The Notes are convertible at the option of the holders at any time prior to the close of business on the business day immediately preceding May 15, 2025, only under the following circumstances: (i) during any fiscal quarter commencing after the fiscal quarter ended on December 31, 2020 (and only during such fiscal quarter), if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding fiscal quarter is greater than or equal to 130% of the conversion price for the Notes on each applicable trading day; (ii) during the five business day period after any ten consecutive trading day period (the “measurement period”) in which the trading price (as defined in the Indenture) per $1,000 principal amount of the Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate for the Notes on each such trading day; (iii) if the Company calls such Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date, but only with respect to the Notes called (or deemed called) for redemption; and (iv) upon the occurrence of specified corporate events, as specified in the Indenture. On or after May 15, 2025 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders of the Notes may convert all or any portion of their Notes at any time, regardless of the foregoing conditions. During the three months ended December 31, 2021, the conditional conversion feature of the Notes was triggered, based on the price of the Company’s common stock, as the last reported sale price of the Company’s common stock was greater than or equal to 130% of the then applicable conversion price for the Notes for at least 20 trading days during the period of 30 consecutive trading days ending on December 31, 2021, the last trading day of the respective fiscal quarter. Accordingly, the Notes were convertible during the first quarter of 2022 and were classified as a current liability in the Consolidated Financial Statements as of December 31, 2021. During the three months ended September 30, 2022, none of the conditional conversion features of the Notes were triggered, and therefore, the Notes are not convertible during the fourth quarter of 2022, commencing on October 1, 2022. Accordingly, the Company classified the Notes as a long-term liability in its Condensed Consolidated Financial Statements as of September 30, 2022. Whether the Notes will be convertible following the fourth fiscal quarter of 2022 will depend on the satisfaction of the conversion conditions in the future. Under the original terms of the Indenture, upon conversion, the Company could satisfy its conversion obligation by paying or delivering cash, shares of its common stock, or a combination thereof, at the Company’s election, in the manner and subject to the terms and conditions provided in the Indenture. On December 13, 2021, the Company irrevocably elected to fix its settlement method to a combination of cash and shares of the Company’s common stock with the specified cash amount per $1,000 principal amount of Notes of at least $1,000. As a result, for Notes converted on or after December 13, 2021, a converting noteholder will receive (i) up to $1,000 in cash per $1,000 principal amount of Notes and (ii) cash and/or shares of the Company’s common stock, at the Company’s option for any conversion consideration in excess of $1,000. In addition, the Company continues to have the ability to set the specified cash amount per $1,000 principal amount of Notes above $1,000. The initial conversion rate for the Notes is 10.2751 shares of the Company’s common stock per $1,000 principal amount of Notes, which is equivalent to an initial conversion price of approximately $97.32 per share of the Company’s common stock, subject to adjustment under certain circumstances in accordance with the terms of the Indenture. In addition, following certain corporate events that could occur prior to the maturity date of the Notes or if the Company delivers a notice of redemption in respect of the Notes, the Company will, under certain circumstances, increase the conversion rate of the Notes for a holder who elects to convert its Notes (or any portion thereof) in connection with such a corporate event or convert its Notes called (or deemed called) for redemption during the related redemption period (as defined in the Indenture), as the case may be. If the Company undergoes a fundamental change, holders may require, subject to certain exceptions, the Company to repurchase for cash all or any portion of their Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. As of September 30, 2022, none of the criteria for a fundamental change or a conversion rate adjustment had been met. The Company may not redeem the Notes prior to September 20, 2023. The Company may redeem for cash all or any portion of the Notes, at its option, on or after September 20, 2023, if the last reported sale price of the Company’s common stock has been at least 130% of the conversion price for the Notes then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If the Company redeems less than all of the outstanding Notes, at least $150.0 million aggregate principal amount of Notes must be outstanding and not subject to redemption as of the date of the relevant notice of redemption. No sinking fund is provided for in the Notes. Prior to the adoption of ASU 2020-06, convertible debt instruments that could be settled in cash were required to be separated into liability and equity components. The allocation to the liability component was based on the fair value of a similar instrument that did not contain an equity conversion option. Based on this debt-to-equity ratio, debt issuance costs were then allocated to the liability and equity components in a similar manner. Accordingly, at issuance, the Company allocated $461.8 million to the debt liability and $72.7 million to additional paid-in capital, net of applicable issuance costs and deferred taxes. The difference between the principal amount of the Notes and the liability component, inclusive of issuance costs, represented the debt discount, which the Company amortized to interest expense over the term of the Notes using an effective interest rate of 4.18%. The determination of the discount rate required certain estimates and assumptions. Upon adoption of ASU 2020-06, effective January 1, 2022, the Notes are no longer separated into liability and equity components, and are accounted for as a single liability measured at its amortized cost. Refer to Note 1, Organization and Summary of Significant Accounting Policies , for further information. As of September 30, 2022, the remaining life of the Notes and the related issuance cost accretion is approximately 3.0 years. The maximum number of shares issuable upon conversion, including the effect of a fundamental change and subject to other conversion rate adjustments, would be 5.9 million shares. As of September 30, 2022, the if-converted value of the Notes did not exceed the principal amount. The Notes consisted of the following balances reported in the Condensed Consolidated Balance Sheets as of September 30, 2022 and December 31, 2021: September 30, 2022 (2) December 31, (In thousands) Liability: Principal amount $ 575,000 $ 575,000 Unamortized discount — (77,136) Unamortized debt issuance costs (9,197) (9,712) Convertible senior notes, liability component (1) $ 565,803 $ 488,152 Convertible senior notes, equity component $ — $ 72,732 _________________________________________________ (1) Classified as a long-term liability as of September 30, 2022, and a current liability as of December 31, 2021, in the Condensed Consolidated Balance Sheets. (2) Refer to Note 1, Organization and Summary of Significant Accounting Policies , for further information regarding the impact of the adoption of ASU 2020-06, effective January 1, 2022. The following table summarizes the components of interest expense resulting from the Notes recognized in interest and other income (expense), net in the Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2022 and 2021: Three Months Ended September 30, Nine Months Ended September 30, 2022 (1) 2021 2022 (1) 2021 (In thousands) Contractual coupon interest $ 359 $ 359 $ 1,078 $ 1,078 Amortization of discount $ — $ 4,679 $ — $ 13,874 Amortization of debt issuance costs $ 768 $ 589 $ 2,298 $ 1,747 _________________________________________________ (1) Refer to Note 1, Organization and Summary of Significant Accounting Policies , for further information regarding the impact of the adoption of ASU 2020-06, effective January 1, 2022. Convertible Note Hedge and Warrant Transactions In connection with the issuance of the Notes, the Company entered into convertible note hedge and warrant transactions with an affiliate of one of the initial purchasers of the Notes and certain other financial institutions (the “option counterparties”) with respect to the Company’s common stock. The convertible note hedge consists of an option for the Company to purchase up to approximately 5.9 million shares of the Company’s common stock, which is equal to the number of shares of the Company’s common stock underlying the Notes, at an initial strike price of approximately $97.32 per share. The convertible note hedge will expire upon the maturity of the Notes, if not earlier exercised or terminated. The cost of the convertible note hedge was approximately $100.6 million and was accounted for as an equity instrument, which was recorded in additional paid-in capital in the Condensed Consolidated Balance Sheets. The Company recorded a deferred tax asset of $25.8 million at issuance related to the convertible note hedge transaction. The convertible note hedge is expected generally to reduce the potential dilution to the Company’s common stock upon any conversion of Notes and/or offset any cash payments the Company is required to make in excess of the principal amount of converted Notes. Separately from the convertible note hedge, the Company entered into warrant transactions to sell to the option counterparties warrants to acquire, subject to customary anti-dilution adjustments, up to approximately 5.9 million shares of its common stock in the aggregate at an initial strike price of $141.56 per share. The warrants require net share or net cash settlement upon the Company’s election. The Company received aggregate proceeds of approximately $51.3 million for the issuance of the warrants, which was recorded in additional paid-in capital at issuance in the Condensed Consolidated Balance Sheets. The warrants could separately have a dilutive effect to the Company’s common stock to the extent that the market price per share of its common stock exceeds the strike price of the warrants. |
Lessor Leases
Lessor Leases | 9 Months Ended |
Sep. 30, 2022 | |
Leases [Abstract] | |
Lessor Leases | Lessor Leases Sales-Type Leases On a recurring basis, the Company enters into multi-year, sales-type lease agreements, with the majority of such leases varying in length from one The following table presents the Company’s income recognized from sales-type leases for the three and nine months ended September 30, 2022 and 2021: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 (In thousands) Sales-type lease revenues $ 10,115 $ 3,892 $ 34,033 $ 14,503 Cost of sales-type lease revenues (5,357) (1,699) (16,963) (5,678) Selling profit on sales-type lease revenues $ 4,758 $ 2,193 $ 17,070 $ 8,825 The receivables as a result of these types of transactions are collateralized by the underlying equipment leased and consist of the following components at September 30, 2022 and December 31, 2021: September 30, December 31, (In thousands) Net minimum lease payments to be received $ 52,644 $ 31,444 Less: Unearned interest income portion (6,251) (2,388) Net investment in sales-type leases 46,393 29,056 Less: Current portion (1) (12,586) (10,665) Long-term investment in sales-type leases, net $ 33,807 $ 18,391 _________________________________________________ (1) The current portion of the net investment in sales-type leases is included in other current assets in the Condensed Consolidated Balance Sheets. The carrying amount of the Company’s sales-type lease receivables is a reasonable estimate of fair value. The maturity schedule of future minimum lease payments under sales-type leases retained in-house and the reconciliation to the net investment in sales-type leases reported on the Condensed Consolidated Balance Sheets was as follows: September 30, (In thousands) Remaining three months of 2022 $ 3,782 2023 13,314 2024 10,064 2025 8,171 2026 6,387 Thereafter 10,926 Total future minimum sales-type lease payments 52,644 Present value adjustment (6,251) Total net investment in sales-type leases $ 46,393 Operating Leases The Company entered into certain leasing agreements that were classified as operating leases prior to the adoption of ASC 842, Leases . These agreements in place prior to January 1, 2019 continue to be treated as operating leases; however, any leasing agreements entered into on or after January 1, 2019 under these programs are classified and accounted for as sales-type leases in accordance with ASC 842. The operating lease arrangements generally have initial terms of one The following table represents the Company’s income recognized from operating leases for the three and nine months ended September 30, 2022 and 2021: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 (In thousands) Rental income $ 2,327 $ 2,474 $ 7,220 $ 8,278 |
Lessor Leases | Lessor Leases Sales-Type Leases On a recurring basis, the Company enters into multi-year, sales-type lease agreements, with the majority of such leases varying in length from one The following table presents the Company’s income recognized from sales-type leases for the three and nine months ended September 30, 2022 and 2021: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 (In thousands) Sales-type lease revenues $ 10,115 $ 3,892 $ 34,033 $ 14,503 Cost of sales-type lease revenues (5,357) (1,699) (16,963) (5,678) Selling profit on sales-type lease revenues $ 4,758 $ 2,193 $ 17,070 $ 8,825 The receivables as a result of these types of transactions are collateralized by the underlying equipment leased and consist of the following components at September 30, 2022 and December 31, 2021: September 30, December 31, (In thousands) Net minimum lease payments to be received $ 52,644 $ 31,444 Less: Unearned interest income portion (6,251) (2,388) Net investment in sales-type leases 46,393 29,056 Less: Current portion (1) (12,586) (10,665) Long-term investment in sales-type leases, net $ 33,807 $ 18,391 _________________________________________________ (1) The current portion of the net investment in sales-type leases is included in other current assets in the Condensed Consolidated Balance Sheets. The carrying amount of the Company’s sales-type lease receivables is a reasonable estimate of fair value. The maturity schedule of future minimum lease payments under sales-type leases retained in-house and the reconciliation to the net investment in sales-type leases reported on the Condensed Consolidated Balance Sheets was as follows: September 30, (In thousands) Remaining three months of 2022 $ 3,782 2023 13,314 2024 10,064 2025 8,171 2026 6,387 Thereafter 10,926 Total future minimum sales-type lease payments 52,644 Present value adjustment (6,251) Total net investment in sales-type leases $ 46,393 Operating Leases The Company entered into certain leasing agreements that were classified as operating leases prior to the adoption of ASC 842, Leases . These agreements in place prior to January 1, 2019 continue to be treated as operating leases; however, any leasing agreements entered into on or after January 1, 2019 under these programs are classified and accounted for as sales-type leases in accordance with ASC 842. The operating lease arrangements generally have initial terms of one The following table represents the Company’s income recognized from operating leases for the three and nine months ended September 30, 2022 and 2021: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 (In thousands) Rental income $ 2,327 $ 2,474 $ 7,220 $ 8,278 |
Lessee Leases
Lessee Leases | 9 Months Ended |
Sep. 30, 2022 | |
Leases [Abstract] | |
Lessee Leases | Lessee Leases The Company has operating leases for office buildings, data centers, office equipment, and vehicles. The Company’s leases have initial terms of one The maturity schedule of future minimum lease payments under operating leases and the reconciliation to the operating lease liabilities reported on the Condensed Consolidated Balance Sheets was as follows: September 30, (In thousands) Remaining three months of 2022 $ 3,279 2023 13,089 2024 12,041 2025 9,250 2026 8,723 Thereafter 14,306 Total operating lease payments 60,688 Present value adjustment (8,168) Total operating lease liabilities (1) $ 52,520 _________________________________________________ (1) Amount consists of a current and long-term portion of operating lease liabilities of $10.7 million and $41.9 million, respectively. The current portion of the operating lease liabilities is included in accrued liabilities Operating lease costs were $4.0 million and $3.8 million for the three months ended September 30, 2022 and 2021, respectively, and $12.8 million and $11.1 million for the nine months ended September 30, 2022 and 2021, respectively. Short-term lease costs and variable lease costs were immaterial for the three and nine months ended September 30, 2022 and 2021. During the three and nine months ended September 30, 2022, the Company recorded impairment and abandonment charges to operating lease right-of-use assets of $0.3 million and $5.4 million, respectively, in connection with restructuring activities for optimization of certain leased facilities. The impairment and abandonment charges were recorded to selling, general, and administrative expenses on the Company’s Condensed Consolidated Statements of Operations. The following table summarizes supplemental cash flow information related to the Company’s operating leases for the nine months ended September 30, 2022 and 2021: Nine Months Ended September 30, 2022 2021 (In thousands) Cash paid for amounts included in the measurement of lease liabilities $ 13,178 $ 11,774 Right-of-use assets obtained in exchange for new lease liabilities $ 12,177 $ 2,804 The following table summarizes the weighted-average remaining lease term and weighted-average discount rate related to the Company’s operating leases as of September 30, 2022 and December 31, 2021: September 30, December 31, Weighted-average remaining lease term, years 5.2 5.2 Weighted-average discount rate, % 5.6 % 5.5 % |
Commitments and Contingencies
Commitments and Contingencies | 9 Months Ended |
Sep. 30, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Commitments and Contingencies Purchase Obligations In the ordinary course of business, the Company issues purchase orders based on its current manufacturing needs. As of September 30, 2022, the Company had non-cancelable purchase commitments of $186.9 million, of which $115.9 million are expected to be paid within the year ending December 31, 2022. Ransomware Incident On May 4, 2022, the Company determined that certain of its information technology systems were affected by ransomware impacting certain internal systems. Upon detecting the security event, the Company took immediate steps designed to contain the incident and implement its business continuity plans to restore and support continued operations. The Company has contained the incident and restored substantially all of its critical information technology systems. During the three months ended September 30, 2022, the Company incurred $1.0 million of expenses related to the ransomware incident, and during the nine months ended September 30, 2022, the Company incurred $13.5 million of expenses related to the ransomware incident, partially offset by $11.1 million of expected insurance recoveries. Expenses include costs to investigate and remediate the ransomware incident, as well as legal and other professional services, all of which were expensed as incurred. For the three and nine months ended September 30, 2022, the Company included net expenses related to the ransomware incident in cost of revenues of $0.1 million and $0.3 million, respectively; in research and development of $0.2 million and $0.2 million, respectively; and in selling general and administrative expenses of $0.7 million and $1.9 million, respectively, in the Company’s Condensed Consolidated Statements of Operations. Legal Proceedings The Company is currently involved in various legal proceedings. A class action lawsuit was filed against the Company, on June 5, 2019, in the Circuit Court of Cook County, Illinois, Chancery Division, captioned Corey Heard, individually and on behalf of all others similarly situated v. Omnicell, Inc., Case No. 2019-CH-06817 (the “Heard Action”). The complaint seeks class certification, monetary damages in the form of statutory damages for willful and/or reckless or, in the alternative, negligent violation of the Illinois Biometric Information Privacy Act (“BIPA”), and certain declaratory, injunctive, and other relief based on causes of action directed to allegations of violation of BIPA by the Company. The complaint was served on the Company on June 13, 2019. On July 31, 2019, the Company filed a motion to stay or consolidate the case with the action Yana Mazya, et al. v. Northwestern Lake Forest Hospital, et al., Case No. 2018-CH-07161, pending in the Circuit Court of Cook County, Illinois, Chancery Division (the “Mazya Action”). The Court subsequently, on October 10, 2019, denied the motion, without prejudice, as being moot in view of the dismissal of the claims against the Company in the Mazya Action. The Company filed a motion to dismiss the complaint in the Heard Action on October 31, 2019. The hearing on the Company’s motion to dismiss was held on September 2, 2020. The Court ruled from the bench and dismissed the complaint without prejudice giving plaintiff leave to file an amended complaint by September 30, 2020. Plaintiff filed an amended complaint on September 30, 2020 and the Company subsequently filed a motion to dismiss the amended complaint on October 28, 2020, which was fully briefed, but the Court had not heard oral argument on the motion. The parties entered into a settlement agreement on January 25, 2022, (the “Settlement Agreement”). On February 1, 2022, the Court granted preliminary approval of the settlement. Following preliminary approval, plaintiff conducted discovery to identify class members and to determine the class size. Pursuant to the terms of the Settlement Agreement, and following class size discovery, the parties will participate in non-binding mediation, which is currently scheduled for November 21, 2022 to determine if the settlement will move forward. The Court has scheduled an interim status conference for November 30, 2022. Subject to final approval of the settlement, the Company intends to defend the lawsuit vigorously. As required under ASC 450, Contingencies , the Company accrues for contingencies when it believes that a loss is probable and that it can reasonably estimate the amount of any such loss. The Company has not recorded any material accrual for contingent liabilities associated with the legal proceeding described above based on its belief that any potential material loss, while reasonably possible, is not probable. Further, any possible range of loss in this matter cannot be reasonably estimated at this time or is not deemed material. The Company believes that it has valid defenses with respect to the legal proceeding pending against it. However, litigation is inherently unpredictable, and it is possible that cash flows or results of operations could be materially affected in any particular period by the unfavorable resolution of the legal proceeding or because of the diversion of management’s attention and the creation of significant expenses. |
Income Taxes
Income Taxes | 9 Months Ended |
Sep. 30, 2022 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Income Taxes The Company generally provides for income taxes in interim periods based on the estimated annual effective tax rate for the year, adjusting for discrete items in the quarter in which they arise. The annual effective tax rate before discrete items was 17.8% and 28.2% for the nine months ended September 30, 2022 and 2021, respectively. The Company has executed various global operational centralization activities and legal entity rationalization in recent years. The Company did not recognize any gains or losses from such activities during the nine months ended September 30, 2022, and recognized an immaterial gain from such activities during the nine months ended September 30, 2021. The Company recognized a discrete tax benefit related to equity compensation in the amount of $6.2 million and $14.5 million for the nine months ended September 30, 2022 and 2021, respectively. The 2022 annual effective tax rate before discrete items differed from the statutory rate of 21% primarily due to the favorable impact of the research and development credits and foreign-derived intangible income benefit (“FDII”) deduction, partially offset by unfavorable impact of state income taxes, non-deductible compensation and equity charges, and Global Intangible Low-Taxed Income tax inclusion. The 2021 annual effective tax rate before discrete items differed from the statutory rate of 21% primarily due to the unfavorable impact of state income taxes, non-deductible compensation and equity charges, and non-deductible transaction costs related to merger and acquisition activities, partially offset by the favorable impact of research and development credits and an FDII deduction. On August 16, 2022, the Inflation Reduction Act of 2022, (the “IRA”), was signed into law. Among other things, the IRA imposes a 15% corporate alternative minimum tax for tax years beginning after December 31, 2022, levies a 1% excise tax on net stock repurchases after December 31, 2022, and provides tax incentives to promote clean energy. The Company is in the process of analyzing the potential impacts of the IRA’s provisions. However, these provisions are not currently expected to have a material impact on the Company’s results of operations or financial position. On March 11, 2021, the President of the United States signed into law the “American Rescue Plan Act of 2021” (the “ARP Act”), which provides additional economic stimulus and tax credits, including the expansion and modification of the employee retention tax credit enacted by the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”) and the refundable tax credits for COVID-related paid sick and family leave enacted by the Family First Act. The ARP Act further expands the “covered employees” definition for purposes of Section 162(m) of the Internal Revenue Code of 1986, as amended, used in determining the limitation on the deduction for excessive employee remuneration rules to be applicable for taxable years beginning after December 31, 2026. The provisions of the ARP Act did not have a material impact on the Company’s income taxes. As of September 30, 2022 and December 31, 2021, the Company had gross unrecognized tax benefits of $9.4 million and $9.0 million, respectively. It is the Company’s policy to classify accrued interest and penalties as part of unrecognized tax benefits, but to record them in interest and other income (expense), net in the Condensed Consolidated Statements of Operations. As of September 30, 2022 and December 31, 2021, the amount of accrued interest and penalties was $0.4 million and $0.6 million, respectively. The Company files income tax returns in the United States and various state and foreign jurisdictions. In the normal course of business, the Company is subject to examinations by taxing authorities, including major jurisdictions such as the United States, Germany, Italy, Netherlands, and the United Kingdom. With few exceptions, as of September 30, 2022, the Company was no longer subject to U.S., state, and foreign tax examinations for years before 2018, 2017, and 2017, respectively. Although the Company believes it has adequately provided for unrecognized tax benefits, the provisions on these positions may change as revised estimates are made or the underlying matters are settled or otherwise resolved. It is not possible at this time to reasonably estimate changes in the unrecognized tax benefits within the next twelve months. |
Employee Benefits and Share-Bas
Employee Benefits and Share-Based Compensation | 9 Months Ended |
Sep. 30, 2022 | |
Share-Based Payment Arrangement [Abstract] | |
Employee Benefits and Share-Based Compensation | Employee Benefits and Share-Based Compensation Stock-Based Plans For a detailed explanation of the Company’s stock plans, refer to Note 14, Employee Benefits and Share-Based Compensation , of the audited Consolidated Financial Statements and accompanying Notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on February 25, 2022. Share-Based Compensation Expense The following table sets forth the total share-based compensation expense recognized in the Company’s Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2022 and 2021: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 (In thousands) Cost of product and service revenues $ 2,203 $ 1,909 $ 6,607 $ 5,890 Research and development 3,054 1,998 7,912 5,429 Selling, general, and administrative 12,053 9,759 36,212 27,158 Total share-based compensation expense $ 17,310 $ 13,666 $ 50,731 $ 38,477 Employee Stock Purchase Plan (“ESPP”) The following assumptions were used to value shares under the ESPP for the three and nine months ended September 30, 2022 and 2021: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Expected life, years 0.5 - 2.0 0.5 - 2.0 0.5 - 2.0 0.5 - 2.0 Expected volatility, % 28.8% - 44.8% 27.4% - 46.6% 28.8% - 45.6% 27.4% - 53.5% Risk-free interest rate, % 0.1% - 3.2% 0.1% - 1.5% 0.1% - 3.2% 0.1% - 2.6% Dividend yield, % — % — % — % — % For the nine months ended September 30, 2022 and 2021, employees purchased approximately 316,000 and 287,000 shares of common stock, respectively, under the ESPP at a weighted-average price of $67.63 and $62.14, respectively. As of September 30, 2022, the unrecognized compensation cost related to the shares to be purchased under the ESPP was approximately $3.9 million and is expected to be recognized over a weighted-average period of 1.5 years. Stock Options The following assumptions were used to value stock options granted pursuant to the Company’s 2009 Equity Incentive Plan, as amended, (the “2009 Plan”) for the nine months ended September 30, 2021. There were no stock options granted during the three and nine months ended September 30, 2022, and the three months ended September 30, 2021. Nine Months Ended September 30, 2021 Expected life, years 4.9 Expected volatility, % 30.1 % Risk-free interest rate, % 0.6 % Estimated forfeiture rate, % 7.9 % Dividend yield, % — % The following table summarizes the stock option activity during the nine months ended September 30, 2022: Number of Weighted-Average Weighted-Average Aggregate (In thousands, except per share data) Outstanding at December 31, 2021 2,954 $ 67.35 6.9 $ 334,119 Granted — — Exercised (341) 53.24 Expired (6) 74.37 Forfeited (109) 85.49 Outstanding at September 30, 2022 2,498 $ 68.47 6.3 $ 53,660 Exercisable at September 30, 2022 1,792 $ 62.36 5.8 $ 47,120 Vested and expected to vest at September 30, 2022 and thereafter 2,446 $ 68.08 6.3 $ 53,202 The weighted-average fair value per share of options granted during the nine months ended September 30, 2021 was $33.89. The intrinsic value of options exercised during the three months ended September 30, 2022 and 2021 was $7.6 million and $26.0 million, respectively, and during the nine months ended September 30, 2022 and 2021 was $23.1 million and $56.8 million, respectively. As of September 30, 2022, total unrecognized compensation cost related to unvested stock options was $20.1 million, which is expected to be recognized over a weighted-average vesting period of 1.6 years. Restricted Stock Units (“RSUs”) The following table summarizes the RSU activity under the 2009 Plan during the nine months ended September 30, 2022: Number of Weighted-Average Weighted-Average Aggregate (In thousands, except per share data) Outstanding at December 31, 2021 763 $ 119.93 1.6 $ 137,696 Granted (Awarded) 663 117.63 Vested (Released) (197) 107.82 Forfeited (90) 124.71 Outstanding and unvested at September 30, 2022 1,139 $ 120.30 1.7 $ 99,156 As of September 30, 2022, total unrecognized compensation cost related to RSUs was $111.1 million, which is expected to be recognized over the remaining weighted-average vesting period of 3.2 years. Restricted Stock Awards (“RSAs”) The following table summarizes the RSA activity under the 2009 Plan during the nine months ended September 30, 2022: Number of Weighted-Average (In thousands, except per share data) Outstanding at December 31, 2021 11 $ 137.36 Granted (Awarded) 13 109.39 Vested (Released) (11) 137.36 Outstanding and unvested at September 30, 2022 13 $ 109.39 As of September 30, 2022, total unrecognized compensation cost related to RSAs was $0.8 million, which is expected to be recognized over the remaining weighted-average vesting period of 0.6 years. Performance-Based Stock Unit Awards (“PSUs”) The following table summarizes the PSU activity under the 2009 Plan during the nine months ended September 30, 2022: Number of Weighted-Average (In thousands, except per share data) Outstanding at December 31, 2021 144 $ 118.71 Granted 78 155.27 Additional granted based on performance achievement 51 156.79 Vested (87) 119.09 Forfeited (14) 145.80 Outstanding and unvested at September 30, 2022 172 $ 144.30 As of September 30, 2022, total unrecognized compensation cost related to PSUs was approximately $8.8 million, which is expected to be recognized over the remaining weighted-average vesting period of 1.2 years. Summary of Shares Reserved for Future Issuance under Equity Incentive Plans The Company had the following ordinary shares reserved for future issuance under its equity incentive plans as of September 30, 2022: Number of Shares (In thousands) Share options outstanding 2,498 Non-vested restricted stock awards 1,324 Shares authorized for future issuance 1,433 ESPP shares available for future issuance 603 Total shares reserved for future issuance 5,858 Stock Repurchase Programs On August 2, 2016, the Company’s Board of Directors (the “Board”) authorized a stock repurchase program providing for the repurchase of up to $50.0 million of the Company’s common stock (the “2016 Repurchase Program”). The 2016 Repurchase Program is in addition to the stock repurchase program approved by the Board on November 4, 2014 providing for the repurchase of up to $50.0 million of the Company’s common stock (the “2014 Repurchase Program”). During the first quarter of 2022, the 2014 Repurchase Program was completed, and as of September 30, 2022, the maximum dollar value of shares that may yet be purchased under the 2016 Repurchase Program was $2.7 million. The 2016 Repurchase Program does not obligate the Company to repurchase any specific number of shares, and the Company may terminate or suspend the 2016 Repurchase Program at any time. During the nine months ended September 30, 2022, the Company repurchased approximately 389,300 shares of its common stock under the repurchase programs at an average price of $134.11 per share for an aggregate purchase price of approximately $52.2 million. During the three months ended September 30, 2022 and three and nine months ended September 30, 2021, the Company did not repurchase any of its outstanding common stock under the repurchase programs. |
Restructuring Expenses
Restructuring Expenses | 9 Months Ended |
Sep. 30, 2022 | |
Restructuring and Related Activities [Abstract] | |
Restructuring Expenses | Restructuring Expenses During 2020, the Company announced a company-wide organizational realignment initiative in order to more effectively align its organizational infrastructure and operations with the industry vision of the Autonomous Pharmacy. In the first quarter of 2021, the Company continued its organizational realignment initiative, incurring $2.0 million of employee severance costs and related expenses. During the first quarter of 2022, the Company initiated certain domestic and international restructuring initiatives, in order to enhance and streamline certain engineering functions for its domestic operations, and to realign its international sales organization to better serve its customers in various international markets. During the third quarter of 2022, the Company initiated restructuring initiatives associated with the integration and functionalization of certain acquisitions, primarily the 340B Link business acquisition, to further accelerate the expansion of the Company’s pharmacy inventory management capabilities. During the three and nine months ended September 30, 2022, the restructuring plans incurred $1.8 million and $5.3 million, respectively, of employee severance costs and related expenses. As of September 30, 2022, the unpaid balance related to these restructuring plans was $2.2 million. The following table summarizes the total restructuring expense recognized in the Company’s Condensed Consolidated Statements of Operations for the three months ended September 30, 2022 and the nine months ended September 30, 2022 and 2021: Three Months Ended September 30, Nine Months Ended September 30, 2022 2022 2021 (In thousands) Cost of product and service revenues $ 444 $ 600 $ 389 Research and development 272 1,866 105 Selling, general, and administrative 1,078 2,855 1,526 Total restructuring expense $ 1,794 $ 5,321 $ 2,020 |
Organization and Summary of S_2
Organization and Summary of Significant Accounting Policies (Policies) | 9 Months Ended |
Sep. 30, 2022 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements reflect, in the opinion of management, all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the financial position of the Company as of September 30, 2022 and December 31, 2021, the results of operations and comprehensive income for the three and nine months ended September 30, 2022 and 2021, and cash flows for the nine months ended September 30, 2022 and 2021. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) have been condensed or omitted in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). These unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and accompanying Notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on February 25, 2022, except as discussed in the section entitled “Recently Adopted Authoritative Guidance” below. The Company’s results of operations and comprehensive income for the three and nine months ended September 30, 2022, and cash flows for the nine months ended September 30, 2022 are not necessarily indicative of results that may be expected for the year ending December 31, 2022, or for any future period. |
Principles of Consolidation | Principles of Consolidation The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. On January 10, 2022, the Company completed its acquisition of Hub and Spoke Innovations Limited (“Hub and Spoke Innovations”). The Condensed Consolidated Financial Statements include the results of operations of this recently acquired company, commencing as of the acquisition date. The significant accounting policies of the acquired business have been aligned to conform to the accounting policies of Omnicell. |
Use of Estimates | Use of Estimates The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company’s Condensed Consolidated Financial Statements and accompanying Notes. These estimates are based on historical experience and various other assumptions that management believes to be reasonable. Although these estimates are based on management’s best knowledge of current events and actions that may impact the Company in the future, actual results may be different from the estimates. The Company’s critical accounting policies are those that affect its financial statements materially and involve difficult, subjective, or complex judgments by management. As of September 30, 2022, the Company is not aware of any events or circumstances that would require an update to its estimates, judgments, or revisions to the carrying value of its assets or liabilities. |
Segment Reporting | Segment Reporting The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company’s Chief Operating Decision Maker (“CODM”) is its Chief Executive Officer. The CODM allocates resources and evaluates the performance of the Company at the consolidated level using information about its revenues, gross profit, income from operations, and other key financial data. All significant operating decisions are based upon an analysis of the Company as one operating segment, which is the same as its reporting segment. |
Recently Adopted and Issued Authoritative Guidance | Recently Adopted Authoritative Guidance In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06 Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40) . The update simplifies the accounting for convertible debt instruments by reducing the number of accounting models and the number of embedded conversion features that could be recognized separately from the primary contract. ASU 2020-06 also enhances transparency and improves disclosures for convertible instruments and earnings per share guidance. ASU 2020-06 also requires the application of the if-converted method for calculating diluted earnings per share and the treasury stock method is no longer permitted for convertible instruments. This update permits the use of either the modified retrospective or fully retrospective method of transition. The Company adopted ASU 2020-06 on January 1, 2022, using the modified retrospective method of transition. Upon adoption of ASU 2020-06, the previously separated equity component and associated debt issuance costs for the Company’s outstanding convertible senior notes were reclassified to the liability component, thereby eliminating the subsequent amortization of the debt discount as interest expense. In addition, the Company derecognized the deferred tax liability related to the equity component. In December 2021, the Company made an irrevocable election under the indenture to require the principal portion of the Company’s convertible senior notes to be settled in cash and any conversion consideration in excess of the principal portion in cash and/or shares of the Company’s common stock at the Company’s option upon conversion. Following the irrevocable election, only the amounts expected to be settled in excess of the principal portion are considered dilutive in calculating earnings per share under the if-converted method. The Company’s adoption of the update impacted the Condensed Consolidated Balance Sheets at the beginning of the period of adoption as follows: January 1, 2022 Pre-ASU 2020-06 Balances ASU 2020-06 Adoption Impact Post-ASU 2020-06 Balances (In thousands) Long-term deferred tax assets $ 15,883 $ (452) $ 15,431 Convertible senior notes, net 488,152 75,353 563,505 Long-term deferred tax liabilities 51,705 (19,572) 32,133 Additional paid-in capital 1,024,580 (72,742) 951,838 Retained earnings 368,571 16,509 385,080 Adoption of the update did not have an impact on the Company’s Condensed Consolidated Statements of Operations or Condensed Consolidated Statements of Cash Flows as of January 1, 2022. Refer to Note 10, Convertible Senior Notes, for further information regarding the Company’s convertible senior notes. Recently Issued Authoritative Guidance In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers . The update addresses diversity in practice by requiring that an acquirer recognize and measure contract assets and liabilities acquired in a business combination in accordance with Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers. The guidance will be applied prospectively to acquisitions occurring on or after the effective date. ASU 2021-08 will be effective for the Company beginning January 1, 2023, and early adoption is permitted. The Company is currently evaluating the impact ASU 2021-08 will have on its Condensed Consolidated Financial Statements. No other recently issued and effective authoritative guidance is expected to have a material impact on the Company’s Condensed Consolidated Financial Statements through the reporting date. |
Business Combinations | The Company accounted for its acquisitions in accordance with ASC 805, Business Combinations . The tangible and intangible assets acquired and liabilities assumed were recorded at fair value on the respective acquisition dates. Intangible assets eligible for recognition separate from goodwill were those that satisfied either the contractual or legal criterion or the separability criterion, each as set forth in the accounting guidance. The preliminary fair values reflect management’s best estimates based on information available at the respective acquisition dates and may change as additional information is received over the measurement period, which will end no later than one year from the respective acquisition date. The Company believes that the fair values assigned to the assets acquired and liabilities assumed are based on reasonable assumptions and estimates that market participants would use. Actual results may differ from these estimates and assumptions. The Company’s Condensed Consolidated Financial Statements include the results of operations of each acquired company, commencing as of their respective acquisition dates. Acquisition-related costs were expensed as incurred, and are included in selling, general, and administrative expenses in the Company’s Condensed Consolidated Statements of Operations. The customer relationships intangible assets represent the fair values of the underlying relationships and agreements with each acquired company’s customers. The acquired technology intangible assets represent the fair values of the portfolio of SaaS solutions that have reached technological feasibility and were part of the respective acquired company’s offerings at their respective acquisition dates. The backlog intangible asset represents contractually committed future billings associated with MarkeTouch Media customer contracts. The trade names intangible asset represents the fair value of brand and name recognition associated with the marketing of certain FDS Amplicare SaaS solutions. The fair values of the customer relationships and backlog intangible assets were determined based on the excess earnings method, and the fair values of the acquired technology and trade names intangible assets were determined based on the relief-from-royalty method. The key assumptions used in estimating the fair values of intangible assets included forecasted financial information; customer attrition rates; royalty rate of 10.0% for the acquired technology intangible assets for both FDS Amplicare and MarkeTouch Media; royalty rate of 2.0% for the FDS Amplicare trade names intangible asset; discount rate of 13.0% for the FDS Amplicare acquisition; discount rate of 15.0% for the ReCept acquisition; discount rate of 11.5% for the MarkeTouch Media acquisition; and certain other assumptions. The customer relationships and acquired technology intangible assets are being amortized using a double-declining method of amortization as such method better represents the economic benefits to be obtained. The backlog and trade names intangible assets are being amortized over their respective estimated useful lives using the straight-line method of amortization. |
Revenue Recognition | Revenue Recognition The Company earns revenues from sales of its products and related services, which are sold in the healthcare industry, its principal market. The Company’s customer arrangements typically include one or more of the following revenue categories: Connected devices, software licenses, and other. Software-enabled connected devices and software licenses that manage and regulate the storage and dispensing of pharmaceuticals, consumables blister cards, and packaging equipment and other supplies. This revenue category is often sold through long-term, sole-source agreements with multi-year co-development plans. Solutions in this category include, but are not limited to, XT Series automated dispensing systems, the XR2 Automated Central Pharmacy System, IVX Station and IV compounding automation solutions. Technical services. Post-installation technical support and other related services, including phone support, on-site service, parts, and access to unspecified software updates and enhancements, if and when available. This revenue category is often supported by multi-year or annual contractual agreements. Consumables. Medication adherence packaging, labeling, and other one-time use packaging including multimed adherence packaging and single dose blister cards which are used by retail, community, and outpatient pharmacies, as well as by institutional pharmacies serving long-term care and other sites outside the acute care hospital, and are designed to improve patient engagement and adherence to prescriptions. SaaS, subscription software, and technology-enabled services. Emerging software and service solutions which are offered on a subscription basis with fees typically based either on transaction volume or a fee over a specified period of time. Solutions in this category include, but are not limited to, EnlivenHealth inclusive of FDS Amplicare and MarkeTouch Media, 340B solutions, Specialty Pharmacy Services, and services associated with Omnicell One™, Central Pharmacy Dispensing Services, including the XR2 Automated Central Pharmacy System, and Central Pharmacy Compounding Services, including IVX Station and IV compounding automation solutions. The following table summarizes revenue recognition for each revenue category: Revenue Category Timing of Revenue Recognition Income Statement Classification Connected devices, software licenses, and other Point in time, as transfer of control occurs, generally upon installation and acceptance by the customer Product Technical services Over time, as services are provided, typically ratably over the service term Service Consumables Point in time, as transfer of control occurs, generally upon shipment to or receipt by customer Product SaaS, subscription software, and technology-enabled services Over time, as services are provided Service |
Net Income (Loss) Per Share | Basic net income (loss) per share is computed by dividing net income (loss) for the period by the weighted-average number of shares outstanding during the period. In periods of net loss, all potential common shares are anti-dilutive, so diluted net loss per share equals the basic net loss per share. In periods of net income, diluted net income per share is computed by dividing net income for the period by the basic weighted-average number of shares plus any dilutive potential common stock outstanding during the period, using the treasury stock method. Potential common stock includes the effect of outstanding dilutive stock options, restricted stock awards, and restricted stock units, as well as shares the Company could be obligated to issue from its convertible senior notes and warrants, as described in Note 10, Convertible Senior Notes (pre-ASU 2020-06 adoption). For periods prior to the adoption of ASU 2020-06 on January 1, 2022, the Company applied the treasury stock method to calculate the dilutive impact of the convertible senior notes. Upon adoption of ASU 2020-06, effective January 1, 2022, the Company is required to apply the if-converted method for calculating the dilutive impact of the convertible senior notes. Refer to Note 1, Organization and Summary of Significant Accounting Policies , for further information. Any anti-dilutive weighted-average dilutive shares related to stock award plans, convertible senior notes, and warrants are excluded from the computation of the diluted net income per share. |
Fair Value Hierarchy | The Company measures its financial instruments at fair value. The Company’s cash, cash equivalents, and restricted cash are classified within Level 1 of the fair value hierarchy as they are valued primarily using quoted market prices utilizing market observable inputs. The Company’s credit facility is classified within Level 2 as the valuation inputs are based on quoted prices or market observable data of similar instruments. The Company’s convertible senior notes are classified within Level 2 as the valuation inputs are based on quoted prices in an inactive market on the last day in the reporting period. |
Convertible Debt | Prior to the adoption of ASU 2020-06, convertible debt instruments that could be settled in cash were required to be separated into liability and equity components. The allocation to the liability component was based on the fair value of a similar instrument that did not contain an equity conversion option. Based on this debt-to-equity ratio, debt issuance costs were then allocated to the liability and equity components in a similar manner.Upon adoption of ASU 2020-06, effective January 1, 2022, the Notes are no longer separated into liability and equity components, and are accounted for as a single liability measured at its amortized cost. |
Commitments and Contingencies | As required under ASC 450, Contingencies , the Company accrues for contingencies when it believes that a loss is probable and that it can reasonably estimate the amount of any such loss. The Company has not recorded any material accrual for contingent liabilities associated with the legal proceeding described above based on its belief that any potential material loss, while reasonably possible, is not probable. Further, any possible range of loss in this matter cannot be reasonably estimated at this time or is not deemed material. The Company believes that it has valid defenses with respect to the legal proceeding pending against it. However, litigation is inherently unpredictable, and it is possible that cash flows or results of operations could be materially affected in any particular period by the unfavorable resolution of the legal proceeding or because of the diversion of management’s attention and the creation of significant expenses. |
Accounting Policies (Tables)
Accounting Policies (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Accounting Policies [Abstract] | |
Schedule of Adoption Impacts from ASU 2020-06 | The Company’s adoption of the update impacted the Condensed Consolidated Balance Sheets at the beginning of the period of adoption as follows: January 1, 2022 Pre-ASU 2020-06 Balances ASU 2020-06 Adoption Impact Post-ASU 2020-06 Balances (In thousands) Long-term deferred tax assets $ 15,883 $ (452) $ 15,431 Convertible senior notes, net 488,152 75,353 563,505 Long-term deferred tax liabilities 51,705 (19,572) 32,133 Additional paid-in capital 1,024,580 (72,742) 951,838 Retained earnings 368,571 16,509 385,080 |
Business Combinations (Tables)
Business Combinations (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Business Combination and Asset Acquisition [Abstract] | |
Preliminary Allocation of the Purchase Price to the Assets Acquired and the Liabilities Assumed by the Company | The following tables represent the preliminary allocation of the respective purchase price to the assets acquired and the liabilities assumed by the Company as part of each acquisition included in the Company’s Consolidated Balance Sheets, and is reconciled to the respective purchase price transferred: FDS Amplicare (1) ReCept (2) (3) MarkeTouch Media (4) (In thousands) Purchase price transferred: Base purchase price $ 177,000 $ 100,000 $ 82,000 Add: Closing cash 465 6,569 237 Add: Net working capital adjustment 1,654 (7,357) 147 Less: Assumed indebtedness (653) (1,973) (15) Total purchase price transferred $ 178,466 $ 97,239 $ 82,369 FDS Amplicare (1) ReCept (Preliminary) (2) (3) MarkeTouch Media (Preliminary) (4) Fair value of assets acquired and liabilities assumed: Cash and cash equivalents $ 465 $ — $ 237 Accounts receivable and unbilled receivables 5,330 2,383 2,302 Prepaid expenses 506 192 96 Other current assets 45 12,223 — Total current assets 6,346 14,798 2,635 Property and equipment 444 172 177 Operating lease right-of-use assets 2,252 773 602 Goodwill 117,784 77,394 42,273 Intangible assets 70,000 28,100 38,000 Other long-term assets 51 195 2,850 Total assets 196,877 121,432 86,537 Accounts payable 950 219 473 Accrued compensation 1,312 1,756 — Accrued liabilities 1,497 18,499 292 Deferred revenues 1,916 222 347 Long-term deferred tax liabilities 11,686 2,883 — Long-term operating lease liabilities 920 614 206 Other long-term liabilities 130 — 2,850 Total liabilities 18,411 24,193 4,168 Total purchase price $ 178,466 $ 97,239 $ 82,369 Total purchase price, net of cash acquired $ 178,001 $ 90,670 $ 82,132 _________________________________________________ (1) During the fourth quarter of 2021, the Company recorded measurement period adjustments of $1.5 million to goodwill, consisting of an increase in intangible assets, accounts receivable and unbilled receivables, and long-term deferred tax liabilities of $0.4 million, $1.1 million, and $0.1 million, respectively, and a net working capital adjustment of $0.1 million. During the nine months ended September 30, 2022, the Company recorded a measurement period adjustments of $0.4 million to goodwill, consisting of an increase in long-term deferred tax liabilities and accrued liabilities of $0.3 million and $0.1 million, respectively. (2) Closing cash is included in other current assets due to its restrictive nature as cash held for customers. (3) During the nine months ended September 30, 2022, the Company recorded measurement period adjustments of $4.2 million to goodwill, consisting of a purchase price adjustment of $5.2 million and a decrease in long-term deferred tax liabilities of $0.7 million, partially offset by a decrease to other current assets of $1.7 million. |
Summary of Identifiable Intangible Assets Acquired | The identifiable intangible assets acquired and their estimated useful lives for amortization are as follows: FDS Amplicare (1) ReCept MarkeTouch Media Fair value Useful life Fair value Useful life Fair value Useful life (In thousands, except for years) Customer relationships $ 59,900 23 $ 28,100 23 $ 34,100 26 Acquired technology 7,700 5 - 7 — — 2,100 4 Backlog — — — — 1,800 2 Trade names 2,400 5 — — — — Total purchased intangible assets $ 70,000 $ 28,100 $ 38,000 _________________________________________________ (1) During the fourth quarter of 2021, the Company recorded a measurement period adjustment of $0.4 million in customer relationships. |
Pro Forma Financial Information | Three Months Ended September 30, Nine Months Ended September 30, 2021 2021 (In thousands) Pro forma revenues $ 313,170 $ 873,061 Pro forma net income $ 31,157 $ 65,050 |
Revenues (Tables)
Revenues (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Revenue Recognition [Abstract] | |
Summary of Revenue Recognition for Revenue Categories | The following table summarizes revenue recognition for each revenue category: Revenue Category Timing of Revenue Recognition Income Statement Classification Connected devices, software licenses, and other Point in time, as transfer of control occurs, generally upon installation and acceptance by the customer Product Technical services Over time, as services are provided, typically ratably over the service term Service Consumables Point in time, as transfer of control occurs, generally upon shipment to or receipt by customer Product SaaS, subscription software, and technology-enabled services Over time, as services are provided Service |
Disaggregation of Revenues by Revenue Type | The following table summarizes the Company’s revenues disaggregated by revenue type for the three and nine months ended September 30, 2022 and 2021: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 (In thousands) Connected devices, software licenses, and other $ 226,415 $ 195,820 $ 650,125 $ 534,582 Technical services 53,914 53,529 156,386 156,321 Consumables 20,150 18,150 56,121 54,424 SaaS, subscription software, and technology-enabled services 47,580 28,903 135,641 75,657 Total revenues $ 348,059 $ 296,402 $ 998,273 $ 820,984 |
Disaggregation of Revenues by Geographical Location | The following table summarizes the Company’s revenues disaggregated by geographic region, which is determined based on customer location, for the three and nine months ended September 30, 2022 and 2021: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 (In thousands) United States $ 315,755 $ 271,276 $ 898,269 $ 738,411 Rest of world (1) 32,304 25,126 100,004 82,573 Total revenues $ 348,059 $ 296,402 $ 998,273 $ 820,984 _________________________________________________ (1) No individual country represented more than 10% of total revenues. |
Contract Asset and Liabilities | The following table reflects the Company’s contract assets and contract liabilities: September 30, December 31, (In thousands) Short-term unbilled receivables, net (1) $ 28,354 $ 17,208 Long-term unbilled receivables, net (2) 13,815 18,084 Total contract assets $ 42,169 $ 35,292 Short-term deferred revenues, net $ 113,925 $ 112,196 Long-term deferred revenues 34,519 20,194 Total contract liabilities $ 148,444 $ 132,390 _________________________________________________ (1) Included in accounts receivable and unbilled receivables in the Condensed Consolidated Balance Sheets. |
Net Income Per Share (Tables)
Net Income Per Share (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Earnings Per Share [Abstract] | |
Basic and Diluted Net Income Per Share | The basic and diluted net income per share calculations for the three and nine months ended September 30, 2022 and 2021 were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 (In thousands, except per share data) Net income $ 16,774 $ 29,317 $ 34,056 $ 63,868 Weighted-average shares outstanding – basic 44,441 43,648 44,304 43,293 Effect of dilutive securities from stock award plans 943 2,087 1,293 2,086 Effect of convertible senior notes 435 2,156 1,162 1,816 Effect of warrants — 450 — — Weighted-average shares outstanding – diluted 45,819 48,341 46,759 47,195 Net income per share – basic $ 0.38 $ 0.67 $ 0.77 $ 1.48 Net income per share – diluted $ 0.37 $ 0.61 $ 0.73 $ 1.35 Anti-dilutive weighted-average shares related to stock award plans 810 64 689 199 Anti-dilutive weighted-average shares related to convertible senior notes and warrants 5,908 — 5,908 5,908 |
Balance Sheet Components (Table
Balance Sheet Components (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Balance Sheet Components | Balance sheet details as of September 30, 2022 and December 31, 2021 are presented in the tables below: September 30, December 31, (In thousands) Inventories: Raw materials $ 73,221 $ 48,215 Work in process 8,970 11,009 Finished goods 64,905 60,700 Total inventories $ 147,096 $ 119,924 Other current assets: Funds held for customers, including restricted cash (1) $ 35,249 $ 20,405 Net investment in sales-type leases, current portion 12,586 10,665 Prepaid income taxes 1,846 6,656 Other current assets 6,993 10,608 Total other current assets $ 56,674 $ 48,334 Other long-term assets: Capitalized software, net $ 85,186 $ 96,995 Unbilled receivables, net 13,815 18,084 Deferred debt issuance costs 2,333 3,156 Other long-term assets 9,012 9,284 Total other long-term assets $ 110,346 $ 127,519 Accrued liabilities: Operating lease liabilities, current portion $ 10,658 $ 12,947 Customer fund liabilities 35,249 31,727 Advance payments from customers 10,214 8,191 Rebate liabilities 42,363 44,644 Group purchasing organization fees 7,623 7,115 Taxes payable 11,327 3,771 Other accrued liabilities 29,006 24,772 Total accrued liabilities $ 146,440 $ 133,167 _________________________________________________ (1) Includes restricted cash of $17.5 million and $6.6 million as of September 30, 2022 and December 31, 2021, respectively. |
Schedule of Accumulated Other Comprehensive Income (Loss) | The following table summarizes the changes in accumulated balances of other comprehensive income (loss), which consisted of foreign currency translation adjustments, for the three and nine months ended September 30, 2022 and 2021: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 (In thousands) Beginning balance $ (17,372) $ (5,491) $ (8,407) $ (5,522) Other comprehensive loss (6,770) (2,299) (15,735) (2,268) Ending balance $ (24,142) $ (7,790) $ (24,142) $ (7,790) |
Property and Equipment (Tables)
Property and Equipment (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Property, Plant and Equipment [Abstract] | |
Property, Plant and Equipment Balances | The following table represents the property and equipment balances as of September 30, 2022 and December 31, 2021: September 30, December 31, (In thousands) Equipment $ 89,429 $ 89,272 Furniture and fixtures 5,026 7,580 Leasehold improvements 19,766 20,623 Software 73,913 60,856 Construction in progress 23,041 14,757 Property and equipment, gross 211,175 193,088 Accumulated depreciation and amortization (122,819) (121,947) Total property and equipment, net $ 88,356 $ 71,141 |
Summary of Geographic Information for Property and Equipment, Net | The following table summarizes the geographic information for property and equipment, net, as of September 30, 2022 and December 31, 2021: September 30, December 31, (In thousands) United States $ 84,771 $ 66,788 Rest of world (1) 3,585 4,353 Total property and equipment, net $ 88,356 $ 71,141 _________________________________________________ (1) No individual country represented more than 10% of total property and equipment, net. |
Goodwill and Intangible Assets
Goodwill and Intangible Assets (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Changes in Carrying Amount of Goodwill | The following table represents changes in the carrying amount of goodwill: December 31, Additions (1) Measurement Period Adjustments (1) Foreign currency exchange rate fluctuations September 30, (In thousands) Goodwill $ 738,900 2,549 (4,041) (6,114) $ 731,294 _________________________________________________ (1) Refer to Note 2, Business Combinations, for further information. |
Carrying Amounts and Useful Lives of Intangible Assets | The carrying amounts and useful lives of intangible assets as of September 30, 2022 and December 31, 2021 were as follows: September 30, 2022 Gross carrying amount (1) Accumulated Foreign currency exchange rate fluctuations Net carrying Useful life (In thousands, except for years) Customer relationships $ 311,089 $ (94,108) $ (1,880) $ 215,101 4 - 30 Acquired technology 92,066 (61,471) — 30,595 4 - 20 Backlog 1,800 (675) — 1,125 2 Trade names 9,200 (6,371) — 2,829 5 - 12 Patents 2,430 (1,276) — 1,154 2 - 20 Non-compete agreements 600 (400) — 200 3 Total intangibles assets, net $ 417,185 $ (164,301) $ (1,880) $ 251,004 December 31, 2021 Gross carrying amount (1) Accumulated Foreign currency exchange rate fluctuations Net carrying Useful life (In thousands, except for years) Customer relationships $ 309,989 $ (78,093) $ (933) $ 230,963 10 - 30 Acquired technology 95,466 (55,859) 6 39,613 4 - 20 Backlog 1,800 — — 1,800 2 Trade names 9,200 (5,600) 14 3,614 5 - 12 Patents 2,462 (1,186) — 1,276 2 - 20 Non-compete agreements 600 (250) — 350 3 Total intangibles assets, net $ 419,517 $ (140,988) $ (913) $ 277,616 _________________________________________________ (1) The differences in gross carrying amounts between periods are primarily due to the write-off of certain fully amortized intangible assets, partially offset by additions of intangible assets in connection with the Hub and Spoke Innovations acquisition. |
Estimated Future Amortization Expense for Intangible Assets | The estimated future amortization expenses for amortizable intangible assets were as follows: September 30, (In thousands) Remaining three months of 2022 $ 8,463 2023 31,463 2024 23,015 2025 20,970 2026 18,027 Thereafter 149,066 Total $ 251,004 |
Convertible Senior Notes (Table
Convertible Senior Notes (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Debt Disclosure [Abstract] | |
Convertible Debt Balances | The Notes consisted of the following balances reported in the Condensed Consolidated Balance Sheets as of September 30, 2022 and December 31, 2021: September 30, 2022 (2) December 31, (In thousands) Liability: Principal amount $ 575,000 $ 575,000 Unamortized discount — (77,136) Unamortized debt issuance costs (9,197) (9,712) Convertible senior notes, liability component (1) $ 565,803 $ 488,152 Convertible senior notes, equity component $ — $ 72,732 _________________________________________________ (1) Classified as a long-term liability as of September 30, 2022, and a current liability as of December 31, 2021, in the Condensed Consolidated Balance Sheets. (2) Refer to Note 1, Organization and Summary of Significant Accounting Policies , for further information regarding the impact of the adoption of ASU 2020-06, effective January 1, 2022. |
Summary of Components of Interest Expense | The following table summarizes the components of interest expense resulting from the Notes recognized in interest and other income (expense), net in the Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2022 and 2021: Three Months Ended September 30, Nine Months Ended September 30, 2022 (1) 2021 2022 (1) 2021 (In thousands) Contractual coupon interest $ 359 $ 359 $ 1,078 $ 1,078 Amortization of discount $ — $ 4,679 $ — $ 13,874 Amortization of debt issuance costs $ 768 $ 589 $ 2,298 $ 1,747 _________________________________________________ (1) Refer to Note 1, Organization and Summary of Significant Accounting Policies , for further information regarding the impact of the adoption of ASU 2020-06, effective January 1, 2022. |
Lessor Leases (Tables)
Lessor Leases (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Leases [Abstract] | |
Income Recognized from Sales-Type Leases | The following table presents the Company’s income recognized from sales-type leases for the three and nine months ended September 30, 2022 and 2021: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 (In thousands) Sales-type lease revenues $ 10,115 $ 3,892 $ 34,033 $ 14,503 Cost of sales-type lease revenues (5,357) (1,699) (16,963) (5,678) Selling profit on sales-type lease revenues $ 4,758 $ 2,193 $ 17,070 $ 8,825 |
Components of Sales-Type Lease Receivables | The receivables as a result of these types of transactions are collateralized by the underlying equipment leased and consist of the following components at September 30, 2022 and December 31, 2021: September 30, December 31, (In thousands) Net minimum lease payments to be received $ 52,644 $ 31,444 Less: Unearned interest income portion (6,251) (2,388) Net investment in sales-type leases 46,393 29,056 Less: Current portion (1) (12,586) (10,665) Long-term investment in sales-type leases, net $ 33,807 $ 18,391 _________________________________________________ (1) The current portion of the net investment in sales-type leases is included in other current assets in the Condensed Consolidated Balance Sheets. |
Maturity Schedule of Future Minimum Lease Payments under Sales-Type Leases | The maturity schedule of future minimum lease payments under sales-type leases retained in-house and the reconciliation to the net investment in sales-type leases reported on the Condensed Consolidated Balance Sheets was as follows: September 30, (In thousands) Remaining three months of 2022 $ 3,782 2023 13,314 2024 10,064 2025 8,171 2026 6,387 Thereafter 10,926 Total future minimum sales-type lease payments 52,644 Present value adjustment (6,251) Total net investment in sales-type leases $ 46,393 |
Income Recognized from Operating Leases | The following table represents the Company’s income recognized from operating leases for the three and nine months ended September 30, 2022 and 2021: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 (In thousands) Rental income $ 2,327 $ 2,474 $ 7,220 $ 8,278 |
Lessee Leases (Tables)
Lessee Leases (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Leases [Abstract] | |
Maturity Schedule of Future Minimum Lease Payments under Operating Leases and the Reconciliation to the Operating Lease Liabilities | The maturity schedule of future minimum lease payments under operating leases and the reconciliation to the operating lease liabilities reported on the Condensed Consolidated Balance Sheets was as follows: September 30, (In thousands) Remaining three months of 2022 $ 3,279 2023 13,089 2024 12,041 2025 9,250 2026 8,723 Thereafter 14,306 Total operating lease payments 60,688 Present value adjustment (8,168) Total operating lease liabilities (1) $ 52,520 _________________________________________________ (1) Amount consists of a current and long-term portion of operating lease liabilities of $10.7 million and $41.9 million, respectively. The current portion of the operating lease liabilities is included in accrued liabilities |
Supplemental Cash Flow Information Related to Operating Leases | The following table summarizes supplemental cash flow information related to the Company’s operating leases for the nine months ended September 30, 2022 and 2021: Nine Months Ended September 30, 2022 2021 (In thousands) Cash paid for amounts included in the measurement of lease liabilities $ 13,178 $ 11,774 Right-of-use assets obtained in exchange for new lease liabilities $ 12,177 $ 2,804 |
Weighted-Average Remaining Lease Term and Weighted-Average Discount Rate | The following table summarizes the weighted-average remaining lease term and weighted-average discount rate related to the Company’s operating leases as of September 30, 2022 and December 31, 2021: September 30, December 31, Weighted-average remaining lease term, years 5.2 5.2 Weighted-average discount rate, % 5.6 % 5.5 % |
Employee Benefits and Share-B_2
Employee Benefits and Share-Based Compensation (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Share-Based Payment Arrangement [Abstract] | |
Share-Based Compensation Expense | The following table sets forth the total share-based compensation expense recognized in the Company’s Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2022 and 2021: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 (In thousands) Cost of product and service revenues $ 2,203 $ 1,909 $ 6,607 $ 5,890 Research and development 3,054 1,998 7,912 5,429 Selling, general, and administrative 12,053 9,759 36,212 27,158 Total share-based compensation expense $ 17,310 $ 13,666 $ 50,731 $ 38,477 |
Assumptions Used to Value ESPP Shares | The following assumptions were used to value shares under the ESPP for the three and nine months ended September 30, 2022 and 2021: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Expected life, years 0.5 - 2.0 0.5 - 2.0 0.5 - 2.0 0.5 - 2.0 Expected volatility, % 28.8% - 44.8% 27.4% - 46.6% 28.8% - 45.6% 27.4% - 53.5% Risk-free interest rate, % 0.1% - 3.2% 0.1% - 1.5% 0.1% - 3.2% 0.1% - 2.6% Dividend yield, % — % — % — % — % |
Assumptions Used to Value Stock Options Granted | The following assumptions were used to value stock options granted pursuant to the Company’s 2009 Equity Incentive Plan, as amended, (the “2009 Plan”) for the nine months ended September 30, 2021. There were no stock options granted during the three and nine months ended September 30, 2022, and the three months ended September 30, 2021. Nine Months Ended September 30, 2021 Expected life, years 4.9 Expected volatility, % 30.1 % Risk-free interest rate, % 0.6 % Estimated forfeiture rate, % 7.9 % Dividend yield, % — % |
Summary of Share Option Activity | The following table summarizes the stock option activity during the nine months ended September 30, 2022: Number of Weighted-Average Weighted-Average Aggregate (In thousands, except per share data) Outstanding at December 31, 2021 2,954 $ 67.35 6.9 $ 334,119 Granted — — Exercised (341) 53.24 Expired (6) 74.37 Forfeited (109) 85.49 Outstanding at September 30, 2022 2,498 $ 68.47 6.3 $ 53,660 Exercisable at September 30, 2022 1,792 $ 62.36 5.8 $ 47,120 Vested and expected to vest at September 30, 2022 and thereafter 2,446 $ 68.08 6.3 $ 53,202 |
Summary of Restricted Stock Unit Activity | The following table summarizes the RSU activity under the 2009 Plan during the nine months ended September 30, 2022: Number of Weighted-Average Weighted-Average Aggregate (In thousands, except per share data) Outstanding at December 31, 2021 763 $ 119.93 1.6 $ 137,696 Granted (Awarded) 663 117.63 Vested (Released) (197) 107.82 Forfeited (90) 124.71 Outstanding and unvested at September 30, 2022 1,139 $ 120.30 1.7 $ 99,156 |
Summary of Restricted Stock Awards Activity | The following table summarizes the RSA activity under the 2009 Plan during the nine months ended September 30, 2022: Number of Weighted-Average (In thousands, except per share data) Outstanding at December 31, 2021 11 $ 137.36 Granted (Awarded) 13 109.39 Vested (Released) (11) 137.36 Outstanding and unvested at September 30, 2022 13 $ 109.39 |
Summary of Performance-Based Restricted Stock Activity | The following table summarizes the PSU activity under the 2009 Plan during the nine months ended September 30, 2022: Number of Weighted-Average (In thousands, except per share data) Outstanding at December 31, 2021 144 $ 118.71 Granted 78 155.27 Additional granted based on performance achievement 51 156.79 Vested (87) 119.09 Forfeited (14) 145.80 Outstanding and unvested at September 30, 2022 172 $ 144.30 |
Ordinary Shares Reserved for Future Issuance Under Equity Incentive Plans | The Company had the following ordinary shares reserved for future issuance under its equity incentive plans as of September 30, 2022: Number of Shares (In thousands) Share options outstanding 2,498 Non-vested restricted stock awards 1,324 Shares authorized for future issuance 1,433 ESPP shares available for future issuance 603 Total shares reserved for future issuance 5,858 |
Restructuring Expenses (Tables)
Restructuring Expenses (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Restructuring and Related Activities [Abstract] | |
Total Restructuring Expense Recognized in the Condensed Consolidated Statements of Operations | The following table summarizes the total restructuring expense recognized in the Company’s Condensed Consolidated Statements of Operations for the three months ended September 30, 2022 and the nine months ended September 30, 2022 and 2021: Three Months Ended September 30, Nine Months Ended September 30, 2022 2022 2021 (In thousands) Cost of product and service revenues $ 444 $ 600 $ 389 Research and development 272 1,866 105 Selling, general, and administrative 1,078 2,855 1,526 Total restructuring expense $ 1,794 $ 5,321 $ 2,020 |
Organization and Summary of S_3
Organization and Summary of Significant Accounting Policies - Narrative (Details) - segment | 9 Months Ended | 12 Months Ended |
Sep. 30, 2022 | Dec. 31, 2021 | |
Accounting Policies [Abstract] | ||
Number of operating segments | 1 | |
Number of reportable segments | 1 | |
Accounting Standards Update [Extensible Enumeration] | Accounting Standards Update 2020-06 [Member] |
Organization and Summary of S_4
Organization and Summary of Significant Accounting Policies - Schedule of Adoption Impacts from ASU 2020-06 (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Accounting Policies [Line Items] | ||
Long-term deferred tax assets | $ 16,619 | $ 15,883 |
Convertible senior notes, net | 0 | 488,152 |
Long-term deferred tax liabilities | 16,140 | 51,705 |
Additional paid-in capital | 1,030,665 | 1,024,580 |
Retained earnings | $ 419,136 | 368,571 |
ASU 2020-06 Adoption Impact | ||
Accounting Policies [Line Items] | ||
Long-term deferred tax assets | (452) | |
Convertible senior notes, net | 75,353 | |
Long-term deferred tax liabilities | (19,572) | |
Additional paid-in capital | (72,742) | |
Retained earnings | 16,509 | |
Post-ASU 2020-06 Balances | ||
Accounting Policies [Line Items] | ||
Long-term deferred tax assets | 15,431 | |
Convertible senior notes, net | 563,505 | |
Long-term deferred tax liabilities | 32,133 | |
Additional paid-in capital | 951,838 | |
Retained earnings | $ 385,080 |
Business Combinations - Narrati
Business Combinations - Narrative (Details) £ in Millions | Jan. 10, 2022 GBP (£) | Jan. 10, 2022 USD ($) | Dec. 31, 2021 USD ($) | Dec. 29, 2021 USD ($) | Sep. 09, 2021 USD ($) | Sep. 30, 2022 USD ($) | Jan. 10, 2022 USD ($) |
Acquired Finite-Lived Intangible Assets [Line Items] | |||||||
Goodwill | $ 738,900,000 | $ 731,294,000 | |||||
Hub and Spoke Innovations | |||||||
Acquired Finite-Lived Intangible Assets [Line Items] | |||||||
Base purchase price | £ 2.5 | $ 3,400,000 | |||||
Total purchase price transferred | 2.5 | $ 3,400,000 | |||||
Goodwill | 1.9 | 2,500,000 | |||||
Intangible assets | £ 0.8 | $ 1,100,000 | |||||
MarkeTouch Media, LLC | |||||||
Acquired Finite-Lived Intangible Assets [Line Items] | |||||||
Base purchase price | 82,000,000 | ||||||
Total purchase price transferred | 82,369,000 | ||||||
Goodwill | 42,273,000 | ||||||
Intangible assets | 38,000,000 | ||||||
Goodwill expected to be deductible for tax purposes | $ 42,300,000 | ||||||
MarkeTouch Media, LLC | Discount Rate | |||||||
Acquired Finite-Lived Intangible Assets [Line Items] | |||||||
Measurement input used in estimating the fair values of intangible assets | 0.115 | ||||||
MarkeTouch Media, LLC | Acquired Technology | Royalty Rate | |||||||
Acquired Finite-Lived Intangible Assets [Line Items] | |||||||
Measurement input used in estimating the fair values of intangible assets | 0.100 | ||||||
ReCept Holdings, Inc. | |||||||
Acquired Finite-Lived Intangible Assets [Line Items] | |||||||
Base purchase price | $ 100,000,000 | ||||||
Total purchase price transferred | 97,239,000 | ||||||
Goodwill | 77,394,000 | ||||||
Intangible assets | 28,100,000 | ||||||
Goodwill expected to be deductible for tax purposes | $ 0 | ||||||
ReCept Holdings, Inc. | Discount Rate | |||||||
Acquired Finite-Lived Intangible Assets [Line Items] | |||||||
Measurement input used in estimating the fair values of intangible assets | 0.150 | ||||||
FDS Amplicare | |||||||
Acquired Finite-Lived Intangible Assets [Line Items] | |||||||
Base purchase price | $ 177,000,000 | ||||||
Total purchase price transferred | 178,466,000 | ||||||
Goodwill | 117,784,000 | ||||||
Intangible assets | 70,000,000 | ||||||
Goodwill expected to be deductible for tax purposes | $ 0 | ||||||
FDS Amplicare | Discount Rate | |||||||
Acquired Finite-Lived Intangible Assets [Line Items] | |||||||
Measurement input used in estimating the fair values of intangible assets | 0.130 | ||||||
FDS Amplicare | Acquired Technology | Royalty Rate | |||||||
Acquired Finite-Lived Intangible Assets [Line Items] | |||||||
Measurement input used in estimating the fair values of intangible assets | 0.100 | ||||||
FDS Amplicare | Trade Names | Royalty Rate | |||||||
Acquired Finite-Lived Intangible Assets [Line Items] | |||||||
Measurement input used in estimating the fair values of intangible assets | 0.020 |
Business Combinations - Summary
Business Combinations - Summary of Preliminary Purchase Price (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 29, 2021 | Sep. 09, 2021 |
FDS Amplicare | |||
Business Acquisition [Line Items] | |||
Base purchase price | $ 177,000 | ||
Add: Closing cash | 465 | ||
Add: Net working capital adjustment | 1,654 | ||
Less: Assumed indebtedness | (653) | ||
Total purchase price transferred | $ 178,466 | ||
ReCept Holdings, Inc. | |||
Business Acquisition [Line Items] | |||
Base purchase price | $ 100,000 | ||
Add: Closing cash | 6,569 | ||
Add: Net working capital adjustment | (7,357) | ||
Less: Assumed indebtedness | (1,973) | ||
Total purchase price transferred | $ 97,239 | ||
MarkeTouch Media, LLC | |||
Business Acquisition [Line Items] | |||
Base purchase price | $ 82,000 | ||
Add: Closing cash | 237 | ||
Add: Net working capital adjustment | 147 | ||
Less: Assumed indebtedness | (15) | ||
Total purchase price transferred | $ 82,369 |
Business Combinations - Prelimi
Business Combinations - Preliminary Allocation of the Purchase Price to the Assets Acquired and the Liabilities Assumed by the Company (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||||
Jun. 30, 2022 | Dec. 31, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 29, 2021 | Sep. 09, 2021 | |
Business Acquisition [Line Items] | ||||||
Goodwill | $ 738,900 | $ 731,294 | ||||
Measurement period adjustments | (4,041) | |||||
Purchase price adjustments from business acquisitions | 5,484 | $ 0 | ||||
FDS Amplicare | ||||||
Business Acquisition [Line Items] | ||||||
Cash and cash equivalents | $ 465 | |||||
Accounts receivable and unbilled receivables | 5,330 | |||||
Prepaid expenses | 506 | |||||
Other current assets | 45 | |||||
Total current assets | 6,346 | |||||
Property and equipment | 444 | |||||
Operating lease right-of-use assets | 2,252 | |||||
Goodwill | 117,784 | |||||
Intangible assets | 70,000 | |||||
Other long-term assets | 51 | |||||
Total assets | 196,877 | |||||
Accounts payable | 950 | |||||
Accrued compensation | 1,312 | |||||
Accrued liabilities | 1,497 | |||||
Deferred revenues | 1,916 | |||||
Long-term deferred tax liabilities | 11,686 | |||||
Long-term operating lease liabilities | 920 | |||||
Other long-term liabilities | 130 | |||||
Total liabilities | 18,411 | |||||
Total purchase price | 178,466 | |||||
Total purchase price, net of cash acquired | $ 178,001 | |||||
Measurement period adjustments | (1,500) | 400 | ||||
Adjustment, accounts receivable and unbilled receivables | 1,100 | |||||
Adjustment, deferred tax liability, noncurrent | 100 | |||||
Purchase price adjustments from business acquisitions | 100 | |||||
Increase (decrease) in deferred tax liabilities | 300 | |||||
Increase in accrued liabilities | 100 | |||||
FDS Amplicare | Customer relationships | ||||||
Business Acquisition [Line Items] | ||||||
Adjustment, intangibles | 400 | |||||
ReCept Holdings, Inc. | ||||||
Business Acquisition [Line Items] | ||||||
Cash and cash equivalents | $ 0 | |||||
Accounts receivable and unbilled receivables | 2,383 | |||||
Prepaid expenses | 192 | |||||
Other current assets | 12,223 | |||||
Total current assets | 14,798 | |||||
Property and equipment | 172 | |||||
Operating lease right-of-use assets | 773 | |||||
Goodwill | 77,394 | |||||
Intangible assets | 28,100 | |||||
Other long-term assets | 195 | |||||
Total assets | 121,432 | |||||
Accounts payable | 219 | |||||
Accrued compensation | 1,756 | |||||
Accrued liabilities | 18,499 | |||||
Deferred revenues | 222 | |||||
Long-term deferred tax liabilities | 2,883 | |||||
Long-term operating lease liabilities | 614 | |||||
Other long-term liabilities | 0 | |||||
Total liabilities | 24,193 | |||||
Total purchase price | 97,239 | |||||
Total purchase price, net of cash acquired | $ 90,670 | |||||
Measurement period adjustments | (4,200) | |||||
Purchase price adjustments from business acquisitions | 5,200 | |||||
Increase (decrease) in deferred tax liabilities | (700) | |||||
Decrease in other assets, current | $ 1,700 | |||||
MarkeTouch Media, LLC | ||||||
Business Acquisition [Line Items] | ||||||
Cash and cash equivalents | 237 | |||||
Accounts receivable and unbilled receivables | 2,302 | |||||
Prepaid expenses | 96 | |||||
Other current assets | 0 | |||||
Total current assets | 2,635 | |||||
Property and equipment | 177 | |||||
Operating lease right-of-use assets | 602 | |||||
Goodwill | 42,273 | |||||
Intangible assets | 38,000 | |||||
Other long-term assets | 2,850 | |||||
Total assets | 86,537 | |||||
Accounts payable | 473 | |||||
Accrued compensation | 0 | |||||
Accrued liabilities | 292 | |||||
Deferred revenues | 347 | |||||
Long-term deferred tax liabilities | 0 | |||||
Long-term operating lease liabilities | 206 | |||||
Other long-term liabilities | 2,850 | |||||
Total liabilities | 4,168 | |||||
Total purchase price | 82,369 | |||||
Total purchase price, net of cash acquired | $ 82,132 | |||||
Measurement period adjustments | $ (300) |
Business Combinations - Summa_2
Business Combinations - Summary of Identifiable Intangible Assets Acquired (Details) - USD ($) $ in Thousands | 3 Months Ended | |||
Dec. 31, 2021 | Dec. 29, 2021 | Sep. 09, 2021 | Dec. 31, 2021 | |
FDS Amplicare | ||||
Acquired Finite-Lived Intangible Assets [Line Items] | ||||
Fair value | $ 70,000 | |||
FDS Amplicare | Customer relationships | ||||
Acquired Finite-Lived Intangible Assets [Line Items] | ||||
Fair value | $ 59,900 | |||
Useful life | 23 years | |||
Adjustment, intangibles | $ 400 | |||
FDS Amplicare | Acquired technology | ||||
Acquired Finite-Lived Intangible Assets [Line Items] | ||||
Fair value | $ 7,700 | |||
FDS Amplicare | Acquired technology | Minimum | ||||
Acquired Finite-Lived Intangible Assets [Line Items] | ||||
Useful life | 5 years | |||
FDS Amplicare | Acquired technology | Maximum | ||||
Acquired Finite-Lived Intangible Assets [Line Items] | ||||
Useful life | 7 years | |||
FDS Amplicare | Trade names | ||||
Acquired Finite-Lived Intangible Assets [Line Items] | ||||
Fair value | $ 2,400 | |||
Useful life | 5 years | |||
ReCept Holdings, Inc. | ||||
Acquired Finite-Lived Intangible Assets [Line Items] | ||||
Fair value | $ 28,100 | |||
ReCept Holdings, Inc. | Customer relationships | ||||
Acquired Finite-Lived Intangible Assets [Line Items] | ||||
Fair value | $ 28,100 | |||
Useful life | 23 years | |||
MarkeTouch Media, LLC | ||||
Acquired Finite-Lived Intangible Assets [Line Items] | ||||
Fair value | $ 38,000 | |||
MarkeTouch Media, LLC | Customer relationships | ||||
Acquired Finite-Lived Intangible Assets [Line Items] | ||||
Fair value | $ 34,100 | |||
Useful life | 26 years | |||
MarkeTouch Media, LLC | Acquired technology | ||||
Acquired Finite-Lived Intangible Assets [Line Items] | ||||
Fair value | $ 2,100 | |||
Useful life | 4 years | |||
MarkeTouch Media, LLC | Backlog | ||||
Acquired Finite-Lived Intangible Assets [Line Items] | ||||
Fair value | $ 1,800 | |||
Useful life | 2 years |
Business Combinations - Pro For
Business Combinations - Pro Forma Financial Information (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended |
Sep. 30, 2021 | Sep. 30, 2021 | |
Business Combination and Asset Acquisition [Abstract] | ||
Pro forma revenues | $ 313,170 | $ 873,061 |
Pro forma net income | $ 31,157 | $ 65,050 |
Revenues - Narrative (Details)
Revenues - Narrative (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | |
Revenue Recognition [Abstract] | |||||
Fees to GPOs | $ 4,800 | $ 4,400 | $ 13,300 | $ 12,000 | |
Short-term deferred revenues, net | 113,925 | 113,925 | $ 112,196 | ||
Deferred cost of sales | 12,500 | 12,500 | 22,400 | ||
Deferred revenues recognized | 15,200 | 104,200 | |||
Short-term deferred revenues, gross | 134,600 | ||||
Long-term deferred revenues | $ 34,519 | $ 34,519 | $ 20,194 | ||
Remaining performance obligation, recognition period | 10 years | 10 years |
Revenues - Disaggregation of Re
Revenues - Disaggregation of Revenues by Revenue Type (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Revenue from External Customer [Line Items] | ||||
Revenues | $ 348,059 | $ 296,402 | $ 998,273 | $ 820,984 |
Connected devices, software licenses, and other | ||||
Revenue from External Customer [Line Items] | ||||
Revenues | 226,415 | 195,820 | 650,125 | 534,582 |
Technical services | ||||
Revenue from External Customer [Line Items] | ||||
Revenues | 53,914 | 53,529 | 156,386 | 156,321 |
Consumables | ||||
Revenue from External Customer [Line Items] | ||||
Revenues | 20,150 | 18,150 | 56,121 | 54,424 |
SaaS, subscription software, and technology-enabled services | ||||
Revenue from External Customer [Line Items] | ||||
Revenues | $ 47,580 | $ 28,903 | $ 135,641 | $ 75,657 |
Revenues - Disaggregation of _2
Revenues - Disaggregation of Revenues by Geographic Location (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Revenue from External Customer [Line Items] | ||||
Revenues | $ 348,059 | $ 296,402 | $ 998,273 | $ 820,984 |
United States | ||||
Revenue from External Customer [Line Items] | ||||
Revenues | 315,755 | 271,276 | 898,269 | 738,411 |
Rest of world | ||||
Revenue from External Customer [Line Items] | ||||
Revenues | $ 32,304 | $ 25,126 | $ 100,004 | $ 82,573 |
Revenues - Contract Asset and L
Revenues - Contract Asset and Liabilities (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Revenue Recognition [Abstract] | ||
Short-term unbilled receivables, net | $ 28,354 | $ 17,208 |
Long-term unbilled receivables, net | 13,815 | 18,084 |
Total contract assets | 42,169 | 35,292 |
Short-term deferred revenues, net | 113,925 | 112,196 |
Long-term deferred revenues | 34,519 | 20,194 |
Total contract liabilities | $ 148,444 | $ 132,390 |
Net Income Per Share (Details)
Net Income Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 3 Months Ended | 9 Months Ended | ||||||
Sep. 30, 2022 | Jun. 30, 2022 | Mar. 31, 2022 | Sep. 30, 2021 | Jun. 30, 2021 | Mar. 31, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||||||
Net income | $ 16,774 | $ 9,069 | $ 8,213 | $ 29,317 | $ 20,424 | $ 14,127 | $ 34,056 | $ 63,868 |
Weighted-average shares outstanding – basic (in shares) | 44,441 | 43,648 | 44,304 | 43,293 | ||||
Weighted-average shares outstanding — diluted (in shares) | 45,819 | 48,341 | 46,759 | 47,195 | ||||
Net income per share – basic (in dollars per share) | $ 0.38 | $ 0.67 | $ 0.77 | $ 1.48 | ||||
Net income per share – diluted (in dollars per share) | $ 0.37 | $ 0.61 | $ 0.73 | $ 1.35 | ||||
Restricted Stock Awards | ||||||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||||||
Effect of dilutive securities (in shares) | 943 | 2,087 | 1,293 | 2,086 | ||||
Anti-dilutive weighted-average shares (in shares) | 810 | 64 | 689 | 199 | ||||
Convertible Senior Notes | ||||||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||||||
Effect of dilutive securities (in shares) | 435 | 2,156 | 1,162 | 1,816 | ||||
Warrants | ||||||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||||||
Effect of dilutive securities (in shares) | 0 | 450 | 0 | 0 | ||||
Convertible Senior Notes and Warrants | ||||||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||||||
Anti-dilutive weighted-average shares (in shares) | 5,908 | 0 | 5,908 | 5,908 |
Cash and Cash Equivalents and_2
Cash and Cash Equivalents and Fair Value of Financial Instruments (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 | Sep. 30, 2021 |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Cash and cash equivalents | $ 266,402 | $ 349,051 | $ 481,549 |
Cash equivalents | 224,700 | 320,200 | |
Convertible Senior Notes | Convertible Debt | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Short-term debt, fair value | 610,100 | 1,085,000 | |
Long-term debt, current maturities | $ 565,800 | $ 488,152 |
Balance Sheet Components - Bala
Balance Sheet Components - Balance Sheet Components (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 | Sep. 30, 2021 |
Inventories: | |||
Raw materials | $ 73,221 | $ 48,215 | |
Work in process | 8,970 | 11,009 | |
Finished goods | 64,905 | 60,700 | |
Total inventories | $ 147,096 | $ 119,924 | |
Other current assets: | |||
Restricted Cash, Statement of Financial Position [Extensible Enumeration] | Total other current assets | Total other current assets | |
Funds held for customers, including restricted cash | $ 35,249 | $ 20,405 | |
Net investment in sales-type leases, current portion | 12,586 | 10,665 | |
Prepaid income taxes | 1,846 | 6,656 | |
Other current assets | 6,993 | 10,608 | |
Total other current assets | 56,674 | 48,334 | |
Other long-term assets: | |||
Capitalized software, net | 85,186 | 96,995 | |
Unbilled receivables, net | 13,815 | 18,084 | |
Deferred debt issuance costs | 2,333 | 3,156 | |
Other long-term assets | 9,012 | 9,284 | |
Total other long-term assets | $ 110,346 | $ 127,519 | |
Accrued liabilities: | |||
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] | Total accrued liabilities | Total accrued liabilities | |
Operating lease liabilities, current portion | $ 10,658 | $ 12,947 | |
Customer fund liabilities | 35,249 | 31,727 | |
Advance payments from customers | 10,214 | 8,191 | |
Rebate liabilities | 42,363 | 44,644 | |
Group purchasing organization fees | 7,623 | 7,115 | |
Taxes payable | 11,327 | 3,771 | |
Other accrued liabilities | 29,006 | 24,772 | |
Total accrued liabilities | 146,440 | 133,167 | |
Restricted cash | $ 17,489 | $ 6,600 | $ 640 |
Balance Sheet Components - Sche
Balance Sheet Components - Schedule of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
AOCI Attributable to Parent, Net of Tax [Roll Forward] | ||||
Balance at beginning of period | $ 1,092,637 | $ 1,052,572 | $ 1,146,689 | $ 967,503 |
Balance at end of period | 1,135,395 | 1,111,336 | 1,135,395 | 1,111,336 |
Foreign currency translation adjustments | ||||
AOCI Attributable to Parent, Net of Tax [Roll Forward] | ||||
Balance at beginning of period | (17,372) | (5,491) | (8,407) | (5,522) |
Other comprehensive loss | (6,770) | (2,299) | (15,735) | (2,268) |
Balance at end of period | $ (24,142) | $ (7,790) | $ (24,142) | $ (7,790) |
Property and Equipment - Proper
Property and Equipment - Property, Plant and Equipment Balances (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Property, Plant and Equipment [Line Items] | ||
Property and equipment, gross | $ 211,175 | $ 193,088 |
Accumulated depreciation and amortization | (122,819) | (121,947) |
Total property and equipment, net | 88,356 | 71,141 |
Equipment | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, gross | 89,429 | 89,272 |
Furniture and fixtures | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, gross | 5,026 | 7,580 |
Leasehold improvements | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, gross | 19,766 | 20,623 |
Software | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, gross | 73,913 | 60,856 |
Construction in progress | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, gross | $ 23,041 | $ 14,757 |
Property and Equipment - Narrat
Property and Equipment - Narrative (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Property, Plant and Equipment [Abstract] | ||||
Depreciation and amortization expense | $ 5.8 | $ 5.2 | $ 16.7 | $ 14.9 |
Property and Equipment - Summar
Property and Equipment - Summary of Geographic Information for Property and Equipment, Net (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Property, Plant and Equipment [Line Items] | ||
Property and equipment, net | $ 88,356 | $ 71,141 |
United States | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, net | 84,771 | 66,788 |
Rest of world | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, net | $ 3,585 | $ 4,353 |
Goodwill and Intangible Asset_2
Goodwill and Intangible Assets - Changes in Carrying Amount of Goodwill (Details) $ in Thousands | 9 Months Ended |
Sep. 30, 2022 USD ($) | |
Goodwill [Roll Forward] | |
Balance at beginning of period | $ 738,900 |
Additions | 2,549 |
Measurement period adjustments | (4,041) |
Foreign currency exchange rate fluctuations | (6,114) |
Balance at end of period | $ 731,294 |
Goodwill and Intangible Asset_3
Goodwill and Intangible Assets - Carrying Amounts and Useful Lives of Intangible Assets (Details) - USD ($) $ in Thousands | 9 Months Ended | 12 Months Ended |
Sep. 30, 2022 | Dec. 31, 2021 | |
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Gross carrying amount | $ 417,185 | $ 419,517 |
Accumulated amortization | (164,301) | (140,988) |
Foreign currency exchange rate fluctuations | (1,880) | (913) |
Net carrying amount | 251,004 | 277,616 |
Customer relationships | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Gross carrying amount | 311,089 | 309,989 |
Accumulated amortization | (94,108) | (78,093) |
Foreign currency exchange rate fluctuations | (1,880) | (933) |
Net carrying amount | $ 215,101 | $ 230,963 |
Customer relationships | Minimum | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Useful life | 4 years | 10 years |
Customer relationships | Maximum | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Useful life | 30 years | 30 years |
Acquired technology | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Gross carrying amount | $ 92,066 | $ 95,466 |
Accumulated amortization | (61,471) | (55,859) |
Foreign currency exchange rate fluctuations | 0 | 6 |
Net carrying amount | $ 30,595 | $ 39,613 |
Acquired technology | Minimum | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Useful life | 4 years | 4 years |
Acquired technology | Maximum | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Useful life | 20 years | 20 years |
Backlog | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Gross carrying amount | $ 1,800 | $ 1,800 |
Accumulated amortization | (675) | 0 |
Foreign currency exchange rate fluctuations | 0 | 0 |
Net carrying amount | $ 1,125 | $ 1,800 |
Useful life | 2 years | 2 years |
Trade names | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Gross carrying amount | $ 9,200 | $ 9,200 |
Accumulated amortization | (6,371) | (5,600) |
Foreign currency exchange rate fluctuations | 0 | 14 |
Net carrying amount | $ 2,829 | $ 3,614 |
Trade names | Minimum | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Useful life | 5 years | 5 years |
Trade names | Maximum | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Useful life | 12 years | 12 years |
Patents | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Gross carrying amount | $ 2,430 | $ 2,462 |
Accumulated amortization | (1,276) | (1,186) |
Foreign currency exchange rate fluctuations | 0 | 0 |
Net carrying amount | $ 1,154 | $ 1,276 |
Patents | Minimum | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Useful life | 2 years | 2 years |
Patents | Maximum | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Useful life | 20 years | 20 years |
Non-compete agreements | ||
Acquired Finite-Lived Intangible Assets [Line Items] | ||
Gross carrying amount | $ 600 | $ 600 |
Accumulated amortization | (400) | (250) |
Foreign currency exchange rate fluctuations | 0 | 0 |
Net carrying amount | $ 200 | $ 350 |
Useful life | 3 years | 3 years |
Goodwill and Intangible Asset_4
Goodwill and Intangible Assets - Narrative (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Goodwill and Intangible Assets Disclosure [Abstract] | ||||
Amortization expense of intangible assets | $ 8.7 | $ 6.3 | $ 26.7 | $ 18.7 |
Goodwill and Intangible Asset_5
Goodwill and Intangible Assets - Future Amortization Expense for Intangible Assets (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Goodwill and Intangible Assets Disclosure [Abstract] | ||
Remaining three months of 2022 | $ 8,463 | |
2023 | 31,463 | |
2024 | 23,015 | |
2025 | 20,970 | |
2026 | 18,027 | |
Thereafter | 149,066 | |
Net carrying amount | $ 251,004 | $ 277,616 |
Debt and Credit Agreement (Deta
Debt and Credit Agreement (Details) - Line of Credit | Nov. 15, 2019 USD ($) | Sep. 30, 2022 USD ($) | Dec. 31, 2021 USD ($) | Sep. 22, 2020 |
Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank | Minimum | ||||
Debt Instrument [Line Items] | ||||
Commitment fee rate on undrawn commitments | 0.15% | |||
Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank | Maximum | ||||
Debt Instrument [Line Items] | ||||
Commitment fee rate on undrawn commitments | 0.30% | |||
Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank | LIBOR | ||||
Debt Instrument [Line Items] | ||||
Spread on variable interest rate | 1% | |||
Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank | LIBOR | Minimum | ||||
Debt Instrument [Line Items] | ||||
Spread on variable interest rate | 1.25% | |||
Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank | LIBOR | Maximum | ||||
Debt Instrument [Line Items] | ||||
Spread on variable interest rate | 2% | |||
Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank | Federal Funds | ||||
Debt Instrument [Line Items] | ||||
Spread on variable interest rate | 0.50% | |||
Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank | LIBOR Plus 1.00% | Minimum | ||||
Debt Instrument [Line Items] | ||||
Spread on variable interest rate | 0.25% | |||
Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank | LIBOR Plus 1.00% | Maximum | ||||
Debt Instrument [Line Items] | ||||
Spread on variable interest rate | 1% | |||
Revolving Credit Facility | ||||
Debt Instrument [Line Items] | ||||
Outstanding balance for revolving credit | $ 0 | $ 0 | ||
Revolving Credit Facility | Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank | ||||
Debt Instrument [Line Items] | ||||
Term of debt instrument | 5 years | |||
Maximum borrowing capacity | $ 500,000,000 | |||
Revolving Credit Facility | Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank | Calendar Quarters Up To and Including March 31, 2021 | ||||
Debt Instrument [Line Items] | ||||
Maximum secured net leverage ratio | 3.50 | |||
Revolving Credit Facility | Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank | Calendar Quarters After March 31, 2021 | ||||
Debt Instrument [Line Items] | ||||
Maximum secured net leverage ratio | 3 | |||
Incremental Loan Facility | Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank | ||||
Debt Instrument [Line Items] | ||||
Maximum borrowing capacity | 250,000,000 | |||
Letter of Credit | Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank | ||||
Debt Instrument [Line Items] | ||||
Maximum borrowing capacity | 15,000,000 | |||
Swing Line Loan | Wells Fargo Securities, Citizens Bank and JP Morgan Chase Bank | ||||
Debt Instrument [Line Items] | ||||
Maximum borrowing capacity | $ 25,000,000 |
Convertible Senior Notes - Narr
Convertible Senior Notes - Narrative (Details) | 9 Months Ended | ||
Sep. 25, 2020 USD ($) day $ / shares shares | Sep. 30, 2022 USD ($) | Dec. 31, 2021 USD ($) | |
Debt Instrument [Line Items] | |||
Purchase of convertible note hedge | $ 100,600,000 | ||
Proceeds from sale of warrants | 51,300,000 | ||
Convertible Note Hedge | |||
Debt Instrument [Line Items] | |||
Deferred tax asset related to the convertible note hedge transaction | $ 25,800,000 | ||
Convertible Note Hedge Rights | |||
Debt Instrument [Line Items] | |||
Options and warrants to purchase shares (in shares) | shares | 5,900,000 | ||
Strike price (in dollars per share) | $ / shares | $ 97.32 | ||
Warrants | |||
Debt Instrument [Line Items] | |||
Options and warrants to purchase shares (in shares) | shares | 5,900,000 | ||
Strike price (in dollars per share) | $ / shares | $ 141.56 | ||
Convertible Senior Notes | |||
Debt Instrument [Line Items] | |||
Debt instrument, convertible, principal amount of notes, minimum | $ 1,000 | ||
Debt instrument, convertible, maximum cash | 1,000 | ||
Debt instrument, convertible, consideration in excess, amount | 1,000 | ||
Convertible Senior Notes | Convertible Debt | |||
Debt Instrument [Line Items] | |||
Interest rate | 0.25% | ||
Principal amount | $ 575,000,000 | 575,000,000 | $ 575,000,000 |
Additional principal amount subject to purchasers' option | 75,000,000 | ||
Proceeds from issuance of convertible senior notes, net of issuance costs | 559,700,000 | ||
Debt issuance costs incurred and capitalized | $ 15,300,000 | ||
Conversion ratio | 0.0102751 | ||
Conversion price (in dollars per share) | $ / shares | $ 97.32 | ||
Repurchase price as a percent of principal amount | 100% | ||
Aggregate principal amount of Notes that must be outstanding and not subject to redemption if the Company redeems less than all of the Notes | $ 150,000,000 | ||
Convertible senior notes, liability component | 461,800,000 | 565,803,000 | |
Equity component of convertible senior notes | $ 72,700,000 | $ 0 | $ 72,732,000 |
Effective interest rate | 4.18% | ||
Remaining life of debt discount and issuance cost accretion | 3 years | ||
Maximum number of shares issuable upon conversion (in shares) | shares | 5,900,000 | ||
Convertible Senior Notes | Convertible Debt | Period 1 | |||
Debt Instrument [Line Items] | |||
Threshold trading days | day | 20 | ||
Threshold consecutive trading days | day | 30 | ||
Threshold percentage of stock price trigger | 130% | ||
Convertible Senior Notes | Convertible Debt | Period 2 | |||
Debt Instrument [Line Items] | |||
Threshold trading days | day | 5 | ||
Threshold consecutive trading days | day | 10 | ||
Threshold percentage of stock price trigger | 98% |
Convertible Senior Notes - Conv
Convertible Senior Notes - Convertible Debt Balances (Details) - Convertible Debt - Convertible Senior Notes - USD ($) | Sep. 30, 2022 | Dec. 31, 2021 | Sep. 25, 2020 |
Liability: | |||
Principal amount | $ 575,000,000 | $ 575,000,000 | $ 575,000,000 |
Unamortized discount | 0 | (77,136,000) | |
Unamortized debt issuance costs | (9,197,000) | (9,712,000) | |
Convertible senior notes, liability component | 565,803,000 | 461,800,000 | |
Convertible senior notes, liability component | 565,800,000 | 488,152,000 | |
Convertible senior notes, equity component | $ 0 | $ 72,732,000 | $ 72,700,000 |
Convertible Senior Notes - Summ
Convertible Senior Notes - Summary of Components of Interest Expense (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Debt Instrument [Line Items] | ||||
Amortization of discount | $ 0 | $ 13,874 | ||
Amortization of debt issuance costs | 3,121 | 2,570 | ||
Convertible Senior Notes | Convertible Debt | ||||
Debt Instrument [Line Items] | ||||
Contractual coupon interest | $ 359 | $ 359 | 1,078 | 1,078 |
Amortization of discount | 0 | 4,679 | 0 | 13,874 |
Amortization of debt issuance costs | $ 768 | $ 589 | $ 2,298 | $ 1,747 |
Lessor Leases - Narrative (Deta
Lessor Leases - Narrative (Details) | 9 Months Ended |
Sep. 30, 2022 | |
Lease Receivable | Customer Concentration Risk | U.S. Government Hospitals | |
Lessor, Lease, Description [Line Items] | |
Concentration risk percentage | 39% |
Minimum | |
Lessor, Lease, Description [Line Items] | |
Term of sales-type leases | 1 year |
Term of operating leases | 1 year |
Maximum | |
Lessor, Lease, Description [Line Items] | |
Term of sales-type leases | 5 years |
Term of operating leases | 7 years |
Lessor Leases - Income Recogniz
Lessor Leases - Income Recognized from Sales-Type Leases (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Leases [Abstract] | ||||
Sales-type lease revenues | $ 10,115 | $ 3,892 | $ 34,033 | $ 14,503 |
Cost of sales-type lease revenues | (5,357) | (1,699) | (16,963) | (5,678) |
Selling profit on sales-type lease revenues | $ 4,758 | $ 2,193 | $ 17,070 | $ 8,825 |
Lessor Leases - Components of S
Lessor Leases - Components of Sales-Type Lease Receivables (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Leases [Abstract] | ||
Net minimum lease payments to be received | $ 52,644 | $ 31,444 |
Less: Unearned interest income portion | (6,251) | (2,388) |
Net investment in sales-type leases | 46,393 | 29,056 |
Less: Current portion | (12,586) | (10,665) |
Long-term investment in sales-type leases, net | $ 33,807 | $ 18,391 |
Lessor Leases - Maturity Schedu
Lessor Leases - Maturity Schedule of Future Minimum Lease Payments under Sales-Type Leases (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Leases [Abstract] | ||
Remaining three months of 2022 | $ 3,782 | |
2023 | 13,314 | |
2024 | 10,064 | |
2025 | 8,171 | |
2026 | 6,387 | |
Thereafter | 10,926 | |
Net minimum lease payments to be received | 52,644 | $ 31,444 |
Present value adjustment | (6,251) | $ (2,388) |
Total net investment in sales-type leases | $ 46,393 |
Lessor Leases - Income Recogn_2
Lessor Leases - Income Recognized from Operating Leases (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Leases [Abstract] | ||||
Rental income | $ 2,327 | $ 2,474 | $ 7,220 | $ 8,278 |
Lessee Leases - Narrative (Deta
Lessee Leases - Narrative (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Lessee, Lease, Description [Line Items] | ||||
Operating lease cost | $ 4,000 | $ 3,800 | $ 12,800 | $ 11,100 |
Impairment and abandonment of operating lease right-of-use assets related to facilities | $ 300 | $ 5,390 | $ 0 | |
Minimum | ||||
Lessee, Lease, Description [Line Items] | ||||
Term of operating leases | 1 year | 1 year | ||
Maximum | ||||
Lessee, Lease, Description [Line Items] | ||||
Term of operating leases | 12 years | 12 years |
Lessee Leases - Maturity Schedu
Lessee Leases - Maturity Schedule of Future Minimum Lease Payments under Operating Leases and the Reconciliation to the Operating Lease Liabilities (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Leases [Abstract] | ||
Remaining three months of 2022 | $ 3,279 | |
2023 | 13,089 | |
2024 | 12,041 | |
2025 | 9,250 | |
2026 | 8,723 | |
Thereafter | 14,306 | |
Total operating lease payments | 60,688 | |
Present value adjustment | (8,168) | |
Total operating lease liabilities | 52,520 | |
Current portion of operating lease liabilities | 10,658 | $ 12,947 |
Long-term portion of operating lease liabilities | $ 41,862 | $ 39,911 |
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] | Accrued liabilities | Accrued liabilities |
Lessee Leases - Supplemental Ca
Lessee Leases - Supplemental Cash Flow Information Related to Operating Leases (Details) - USD ($) $ in Thousands | 9 Months Ended | |
Sep. 30, 2022 | Sep. 30, 2021 | |
Leases [Abstract] | ||
Cash paid for amounts included in the measurement of lease liabilities | $ 13,178 | $ 11,774 |
Right-of-use assets obtained in exchange for new operating lease liabilities | $ 12,177 | $ 2,804 |
Lessee Leases - Weighted-Averag
Lessee Leases - Weighted-Average Remaining Lease Term and Weighted-Average Discount Rate (Details) | Sep. 30, 2022 | Dec. 31, 2021 |
Leases [Abstract] | ||
Weighted-average remaining lease term | 5 years 2 months 12 days | 5 years 2 months 12 days |
Weighted-average discount rate | 5.60% | 5.50% |
Commitments and Contingencies (
Commitments and Contingencies (Details) $ in Millions | 3 Months Ended | 9 Months Ended |
Sep. 30, 2022 USD ($) | Sep. 30, 2022 USD ($) | |
Loss Contingencies [Line Items] | ||
Non-cancelable purchase commitments | $ 186.9 | $ 186.9 |
Non-cancelable purchase commitments expected to be paid within the year | 115.9 | 115.9 |
Ransomware incident, expense | 1 | 13.5 |
Insurance recoveries | 11.1 | |
Cost of product and service revenues | ||
Loss Contingencies [Line Items] | ||
Ransomware incident, expense, net of insurance recoveries | 0.1 | 0.3 |
Research and development | ||
Loss Contingencies [Line Items] | ||
Ransomware incident, expense, net of insurance recoveries | 0.2 | 0.2 |
Selling, general, and administrative | ||
Loss Contingencies [Line Items] | ||
Ransomware incident, expense, net of insurance recoveries | $ 0.7 | $ 1.9 |
Income Taxes (Details)
Income Taxes (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | |
Income Tax Contingency [Line Items] | |||||
Annual effective tax rate | 17.80% | 28.20% | |||
Discrete tax benefit | $ (543) | $ 5,990 | $ 995 | $ 4,665 | |
Unrecognized tax benefits | 9,400 | 9,400 | $ 9,000 | ||
Accrued interest and penalties | $ 400 | 400 | $ 600 | ||
Equity Compensation | |||||
Income Tax Contingency [Line Items] | |||||
Discrete tax benefit | $ 6,200 | $ 14,500 |
Employee Benefits and Share-B_3
Employee Benefits and Share-Based Compensation - Shared-based Compensation Expense (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||
Share-based compensation expense | $ 17,310 | $ 13,666 | $ 50,731 | $ 38,477 |
Cost of product and service revenues | ||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||
Share-based compensation expense | 2,203 | 1,909 | 6,607 | 5,890 |
Research and development | ||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||
Share-based compensation expense | 3,054 | 1,998 | 7,912 | 5,429 |
Selling, general, and administrative | ||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||
Share-based compensation expense | $ 12,053 | $ 9,759 | $ 36,212 | $ 27,158 |
Employee Benefits and Share-B_4
Employee Benefits and Share-Based Compensation - Assumptions Used to Value ESPP Shares (Details) - ESPP shares available for future issuance - 1997 Plan | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Expected volatility (minimum) | 28.80% | 27.40% | 28.80% | 27.40% |
Expected volatility (maximum) | 44.80% | 46.60% | 45.60% | 53.50% |
Risk-free interest rate (minimum) | 0.10% | 0.10% | 0.10% | 0.10% |
Risk-free interest rate (maximum) | 3.20% | 1.50% | 3.20% | 2.60% |
Dividend yield | 0% | 0% | 0% | 0% |
Minimum | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Expected life | 6 months | 6 months | 6 months | 6 months |
Maximum | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Expected life | 2 years | 2 years | 2 years | 2 years |
Employee Benefits and Share-B_5
Employee Benefits and Share-Based Compensation - Narrative (Details) - USD ($) | 3 Months Ended | 9 Months Ended | ||||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Aug. 02, 2016 | Nov. 04, 2014 | |
The 2016 Repurchase Program | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Value of shares authorized for repurchase under stock repurchase programs (up to) | $ 50,000,000 | |||||
Remaining value of shares authorized for repurchase under stock repurchase programs | $ 2,700,000 | $ 2,700,000 | ||||
2014 Share Repurchase Program | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Value of shares authorized for repurchase under stock repurchase programs (up to) | $ 50,000,000 | |||||
2016 and 2014 Share Repurchase Programs | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Number of shares repurchased (in shares) | 0 | 0 | 389,300 | 0 | ||
Average price of repurchased shares (in dollars per share) | $ 134.11 | |||||
Aggregate purchase price of treasury stock | $ 52,200,000 | |||||
1997 Plan | ESPP shares available for future issuance | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Shares purchased under ESPP (in shares) | 316,000 | 287,000 | ||||
Weighted-average price of shares purchased (in dollars per share) | $ 67.63 | $ 62.14 | ||||
Unrecognized compensation cost | $ 3,900,000 | $ 3,900,000 | ||||
Weighted average period of compensation cost not yet recognized | 1 year 6 months | |||||
2009 Plan | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Stock options granted (in shares) | 0 | 0 | ||||
Weighted-average fair value of options granted (in dollars per share) | $ 33.89 | |||||
Intrinsic value of options exercised | $ 7,600,000 | $ 26,000,000 | $ 23,100,000 | $ 56,800,000 | ||
Unrecognized compensation cost of unvested stock options | 20,100,000 | $ 20,100,000 | ||||
2009 Plan | Stock Options | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Weighted average period of compensation cost not yet recognized | 1 year 7 months 6 days | |||||
2009 Plan | RSUs | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Weighted average period of compensation cost not yet recognized | 3 years 2 months 12 days | |||||
Unrecognized compensation cost | 111,100,000 | $ 111,100,000 | ||||
2009 Plan | RSAs | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Weighted average period of compensation cost not yet recognized | 7 months 6 days | |||||
Unrecognized compensation cost | 800,000 | $ 800,000 | ||||
2009 Plan | PSUs | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Weighted average period of compensation cost not yet recognized | 1 year 2 months 12 days | |||||
Unrecognized compensation cost | $ 8,800,000 | $ 8,800,000 |
Employee Benefits and Share-B_6
Employee Benefits and Share-Based Compensation - Assumptions Used to Value Stock Options Granted (Details) - Stock Options | 9 Months Ended |
Sep. 30, 2021 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Expected life | 4 years 10 months 24 days |
Expected volatility | 30.10% |
Risk-free interest rate | 0.60% |
Estimated forfeiture rate | 7.90% |
Dividend yield | 0% |
Employee Benefits and Share-B_7
Employee Benefits and Share-Based Compensation - Summary of Share Option Activity (Details) - 2009 Plan - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 9 Months Ended | 12 Months Ended |
Sep. 30, 2022 | Sep. 30, 2022 | Dec. 31, 2021 | |
Number of Shares | |||
Outstanding at beginning of period (in shares) | 2,954,000 | ||
Granted (in shares) | 0 | 0 | |
Exercised (in shares) | (341,000) | ||
Expired (in shares) | (6,000) | ||
Forfeited (in shares) | (109,000) | ||
Outstanding at end of period (in shares) | 2,498,000 | 2,498,000 | 2,954,000 |
Exercisable at end of period (in shares) | 1,792,000 | 1,792,000 | |
Vested and expected to vest at end of period (in shares) | 2,446,000 | 2,446,000 | |
Weighted-Average Exercise Price | |||
Outstanding at beginning of period (in dollars per share) | $ 67.35 | ||
Granted (in dollars per share) | 0 | ||
Exercised (in dollars per share) | 53.24 | ||
Expired (in dollars per share) | 74.37 | ||
Forfeited (in dollars per share) | 85.49 | ||
Outstanding at end of period (in dollars per share) | $ 68.47 | 68.47 | $ 67.35 |
Exercisable at end of period (in dollars per share) | 62.36 | 62.36 | |
Vested and expected to vest at end of period (in dollars per share) | $ 68.08 | $ 68.08 | |
Weighted-Average Remaining Years | |||
Outstanding | 6 years 3 months 18 days | 6 years 10 months 24 days | |
Exercisable | 5 years 9 months 18 days | ||
Vested and expected to vest | 6 years 3 months 18 days | ||
Aggregate Intrinsic Value | |||
Outstanding | $ 53,660 | $ 53,660 | $ 334,119 |
Exercisable | 47,120 | 47,120 | |
Vested and expected to vest | $ 53,202 | $ 53,202 |
Employee Benefits and Share-B_8
Employee Benefits and Share-Based Compensation - Summary of Restricted Stock Unit Activity (Details) - RSUs - 2009 Plan - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 9 Months Ended | 12 Months Ended |
Sep. 30, 2022 | Dec. 31, 2021 | |
Number of Shares | ||
Outstanding at beginning of period (in shares) | 763 | |
Granted (Awarded) (in shares) | 663 | |
Vested (Released) (in shares) | (197) | |
Forfeited (in shares) | (90) | |
Outstanding and unvested at end of period (in shares) | 1,139 | 763 |
Weighted-Average Grant Date Fair Value | ||
Outstanding at beginning of period (in dollars per share) | $ 119.93 | |
Granted (Awarded) (in dollars per share) | 117.63 | |
Vested (Released) (in dollars per share) | 107.82 | |
Forfeited (in dollars per share) | 124.71 | |
Outstanding and unvested at end of period (in dollars per share) | $ 120.30 | $ 119.93 |
Weighted-Average Remaining Years | ||
Outstanding and unvested | 1 year 8 months 12 days | 1 year 7 months 6 days |
Aggregate Intrinsic Value | ||
Outstanding and unvested | $ 99,156 | $ 137,696 |
Employee Benefits and Share-B_9
Employee Benefits and Share-Based Compensation - Summary of Restricted Stock Award Activity (Details) - RSAs - 2009 Plan shares in Thousands | 9 Months Ended |
Sep. 30, 2022 $ / shares shares | |
Number of Shares | |
Outstanding at beginning of period (in shares) | shares | 11 |
Granted (Awarded) (in shares) | shares | 13 |
Vested (Released) (in shares) | shares | (11) |
Outstanding and unvested at end of period (in shares) | shares | 13 |
Weighted-Average Grant Date Fair Value | |
Outstanding at beginning of period (in dollars per share) | $ / shares | $ 137.36 |
Granted (Awarded) (in dollars per share) | $ / shares | 109.39 |
Vested (Released) (in dollars per share) | $ / shares | 137.36 |
Outstanding and unvested at end of period (in dollars per share) | $ / shares | $ 109.39 |
Employee Benefits and Share-_10
Employee Benefits and Share-Based Compensation - Summary of Performance-Based Restricted Stock Activity (Details) - Performance-Based Restricted Stock - 2009 Plan shares in Thousands | 9 Months Ended |
Sep. 30, 2022 $ / shares shares | |
Number of Shares | |
Outstanding at beginning of period (in shares) | shares | 144 |
Granted (Awarded) (in shares) | shares | 78 |
Additional granted based on performance achievement (in shares) | shares | 51 |
Vested (Released) (in shares) | shares | (87) |
Forfeited (in shares) | shares | (14) |
Outstanding and unvested at end of period (in shares) | shares | 172 |
Weighted-Average Grant Date Fair Value | |
Outstanding at beginning of period (in dollars per share) | $ / shares | $ 118.71 |
Granted (Awarded) (in dollars per share) | $ / shares | 155.27 |
Additional granted based on performance achievement (in dollars per share) | $ / shares | 156.79 |
Vested (Released) (in dollars per share) | $ / shares | 119.09 |
Forfeited (in dollars per share) | $ / shares | 145.80 |
Outstanding and unvested at end of period (in dollars per share) | $ / shares | $ 144.30 |
Employee Benefits and Share-_11
Employee Benefits and Share-Based Compensation - Summary of Shares Reserved for Future Issuance Under Equity Incentive Plans (Details) shares in Thousands | Sep. 30, 2022 shares |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Shares reserved for future issuance (in shares) | 5,858 |
Share options outstanding | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Shares reserved for future issuance (in shares) | 2,498 |
Non-vested restricted stock awards | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Shares reserved for future issuance (in shares) | 1,324 |
Shares authorized for future issuance | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Shares reserved for future issuance (in shares) | 1,433 |
ESPP shares available for future issuance | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Shares reserved for future issuance (in shares) | 603 |
Restructuring Expenses - Narrat
Restructuring Expenses - Narrative (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Mar. 31, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Restructuring and Related Activities [Abstract] | ||||
Restructuring expenses | $ 1,794 | $ 2,000 | $ 5,321 | $ 2,020 |
Unpaid balance related to restructuring plan | $ 2,200 | $ 2,200 |
Restructuring Expenses - Total
Restructuring Expenses - Total Restructuring Expense Recognized in the Condensed Consolidated Statements of Operations (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Mar. 31, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring expenses | $ 1,794 | $ 2,000 | $ 5,321 | $ 2,020 |
Cost of product and service revenues | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring expenses | 444 | 600 | 389 | |
Research and development | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring expenses | 272 | 1,866 | 105 | |
Selling, general, and administrative | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring expenses | $ 1,078 | $ 2,855 | $ 1,526 |